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ABSTRACT 
 
The fatty acid amides (FAAs) family includes endocannabinoids, such as 
anandamide, as well as endocannabinoid-like molecules, such as N-
palmitoylethanolamine (PEA) and N-oleoylethanolamine (OEA). Members of 
the FAA family show agonist activity at transmitter-gated channels (TRPV1), 
as well as peroxisome poliferator-activated receptors (PPARs). Given that 
FAAs appear to be hydrolysed principally through the action of the enzyme 
fatty acid amide hydrolase, inhibition of FAAH should lead to accumulation of 
a variety of FAAs. Therefore, in this study it was investigated whether 
pharmacological inhibition of FAAH could influence PPAR activity in SH-
SY5Y human neuroblastoma cells or HeLa human cervical carcinoma cells.  
FAAH activity was assessed by monitoring liberation of [3H]-ethanolamine 
from labelled anandamide. FAAH protein and RNA expression were measured 
by immunoblotting and qRT-PCR respectively. Endocannabinoid levels were 
measured by LC-MS/MS. In order to evaluate PPAR activation, a PPRE-linked 
luciferase construct was co-transfected with expression plasmids for either 
33$5 Į ȕ RU Ȗ. Binding to PPAR receptors was assessed with a competitor 
displacement assay (Invitrogen).  
In intact SH-SY5Y cells, sustained FAAH inhibition by URB597 (~75 %) led 
to accumulation of AEA, 2AG and PEA, but not OEA. Treatment with 
URB597, OL135 or PF750, three structurally and functionally distinct FAAH 
inhibitors, induced activation of endogenously expressed PPARs, while no 
activation was observed in FAAH-1 negative HeLa cells. Furthermore, 
exposure to URB597, OL135 or PF750 led to activation of over-expressed 
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PPARs in SH-SY5Y cells. To rule out direct activation of PPARs by the 
FAAH inhibitors, cell-free binding assays showed that URB597, OL135 and 
P) FRXOG QRW ELQG WR 33$5Į 33$5ȕ RU 33$5Ȗ 6XUSULVLQJO\ WUHDWPHQW
with URB597 in HeLa cells led to intracellular accumulation of PEA but not 
AEA, OEA or 2AG. This might be due to inhibition of either FAAH-2 or 
NAAA, both of which are expressed in HeLa cells. Moreover, the presence of 
either URB597 or OL135 led to activation of 33$5ȖUHFHSWRUVRYHU-expressed 
in HeLa cells. 
In conclusion, data in this study showed activation of PPAR nuclear receptors 
in vitro by inhibition of FAAH activity and subsequent augmentation of 
endocannabinoid tone. These data suggest that, at least in a model setup, it is 
possible to modulate the endocannabinoid tone without any previous external 
stimulus of their synthesis and trigger a functional effect.  
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1. INTRODUCTION 
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1.1. Fatty acid amides (FAAs), N-acyl-ethanolamines 
(NAEs) and Endocannabinoids (ECs) 
Fatty acid amides (FAAs, Figure 1.1) are signalling lipids among which the 
most studied compounds found in vivo are: the endogenous cannabinoid N-
arachinoylethanolamine (anandamide, AEA), the anti-inflammatory N-
palmitoylethanolamine (PEA), the regulator of food intake N-
oleoylethanolamine (OEA) and the sleeping inducing factor Cis-9,10-
octadecanoamide (oleamide, ODA) (McKinney et al., 2005). AEA, PEA and 
OEA belong to the N-Acyl Ethanolamines (NAEs) family, while ODA is a 
fatty acid primary amide (FAPA). NAEs have been largely studied in the last 
few years after the discovery of AEA as an endogenous ligand for the 
cannabinoid receptors (Devane et al., 1992). In fact, while the main 
psychoactive compound of Cannabis Sativa (-)-¨9-tetrahydrocannabinol 
(THC) has been isolated in the early 1970s (Gaoni et al., 1971), the 
endogenous cannabinoid system (endocannabinoid system) started to be 
delineated only in the last two decades (Mechoulam et al., 1995).  
 
 
Figure 1.1: Structure of commonly found FAAs (taken from McKinney and 
Cravatt, 2005) 
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Endocannabinoids (ECs) are by definition endogenous ligands for the 
cannabinoid receptors and are believed to follow on-demand biosynthesis. 
There are at least two cannabinoid receptors (CB1 and CB2), and they both 
belong to the Gi/o-protein-coupled class of cell surface receptors. Indeed, they 
are both coupled to pertussis toxin-sensitive inhibition of cAMP formation, 
implicating Gi/o-protein as transducers, and to stimulation of p42/p44 mitogen-
activated protein kinase activity. CB1, but not CB2, receptors signal also via 
ion channels by inhibiting N- and P/Q-type calcium channels and by activating 
A-type and inwardly rectifying potassium channels. Furthermore, CB1 
activation stimulates phosphatidylinositol 3-kinase and protein kinase B 
(Bisogno et al., 2005). There is ample evidence supporting the fact that 
cannabinoids act as retrograde messengers, and their signalling through CB1 
receptors inhibits neurotransmitter release and neurotransmission (Straiker et 
al., 2006). The CB1 receptor was cloned in 1990 (Matsuda et al., 1990) and it 
is mainly but not exclusively expressed in the central nervous system; here, it 
is widely distributed through the forebrain while it has a more localized 
distribution in the hindbrain and spinal cord (Tsou et al., 1998). The CB1 
receptor is the most abundant GPCR expressed in the brain; however, it is also 
found in a variety of peripheral tissues such as adipose tissue, liver, the 
gastrointestinal tract, and pancreas (Di Marzo et al., 2004; Pagotto et al., 2006) 
(Table 1.1). The CB2 receptor was cloned in 1993 (Munro et al., 1993) and it is 
mostly found in peripheral tissues like spleen and testis (Brown et al., 2002) 
and in the immune system (Klein et al., 2003), but it is also believed to be 
expressed in the central nervous system (Onaivi et al., 2006). Recently, two 
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distinct human CB2 isoforms have been identified, with differential tissue 
expression and regulation by cannabinoid receptor ligands (Liu et al., 2009).  
 
Central Nervous 
System 
Genitourinary/ 
Reproductive 
Gastrointestinal Other 
Brain 
Spinal cord 
Kidney 
Placenta 
Prostate 
Testis and sperm 
Uterus 
Ileum 
Liver 
Stomach 
Pancreas 
Adipose 
Lung 
Skeletal Muscle 
Spleen 
 
Table 1.1: Human tissues and organs expressing the CB1 receptor RNA (Di 
Marzo et al., 2004; Pagotto et al., 2006) 
 
ECs are mainly represented by AEA and by 2-arachidonoyl-glycerol (2AG, 
Figure 1.2). AEA can act as an endogenous ligand for CB1 and CB2 receptors 
(Devane et al., 1992) but it is also an endogenous agonist for the vanilloid 
TRPV1 receptor channel (Van der Stelt et al., 2005) and the GRP55 receptor 
(Ryberg et al., 2007). Depending on the tissue and biological response 
measured, it behaves as a partial or full agonist of CB1 receptors. It has very 
low efficacy as CB2 agonist and may even act as antagonist depending on the 
G proteins interacting (Gómez-Ruiz et al., 2007). Instead, 2AG is a full CB1 
and CB2 agonist (Mechoulam et al., 1995) and for this reason many authors 
believe 2AG to be the true ligand for CB2 receptors. ECs and in particular 
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AEA produce a wide range of biological effects. Most notably, AEA plays an 
important role in a cannabinergic pain-suppression system existing within the 
dorsal and lateral periaqueductal gray (PAG) (Walker et al., 1999). However, 
ECs also show antiproliferative, antiemetic, appetite enhancement, and 
anxiolytic activity as well as neuroprotective effects that have strong clinical 
implications (Martin et al., 1999). 
 
 
Figure 1.2: Chemical structures of the two main endocannabinoids and their 
binding and functional properties at cannabinoid receptors (Taken from 
Bisogno et al., 2005) 
 
PEA was extensively studied in the 1950s for its anti-inflammatory properties, 
but research on this compound sped up after discovery of AEA as an 
endogenous ligand for the cannabinoid receptors (Devane et al., 1992). Despite 
being closely related to AEA in terms of structure and belonging to the same 
family, PEA does not bind the cannabinoid receptors (Lo Verme et al., 2005). 
OEA binds with a relatively low affinity to the CB1 but not the CB2 receptor 
(Appendino et al., 2006). This monounsaturated FAE decreases food intake 
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and body weight gain through a cannabinoid receptor-independent mechanism 
(Fu et al., 2003) 
 
The ability compounds such as PEA and OEA to activate the CB1/CB2 receptor 
system is likely to be caused by entourage effect and they may elevate other 
ECs, by inhibiting their catabolism. For example, PEA was shown to potently 
enhance the anti-proliferative effects of AEA on human breast cancer cells at 
least in part by inhibiting the expression of fatty acid amide hydrolase (FAAH) 
the major enzyme responsible for AEA degradation (Di Marzo et al., 2001). 
Moreover, PEA could enhance the TRPV1-mediated effects of AEA and 
capsaicin on calcium influx into cells (De Petrocellis et al., 2002).  
 
Oleamide (octadec-9,10Z-enamide, ODA, Figure 1.1) is a fatty acid primary 
amide first identified as an endogenous lipoamide in the cerebrospinal fluid of 
sleep-deprived cats (Cravatt et al., 1995). ODA is a sleep-inducing factor when 
administered in vivo, also eliciting hypothermia, analgesia and hypo-
locomotion by acting through either the endocannabinoid, GABAergic and 
dopaminergic systems (Fedorova et al., 2001). In vitro, ODA has also been 
reported to induce vasorelaxation in the rat small mesenteric artery (Hoi et al., 
2006). While the biological effects of ODA are well documented, the 
molecular mechanisms and site of action remain elusive. However, in vitro, 
ODA can inhibit gap junction formation (Boger et al., 1998), modulate GABA 
(Yost et al., 1998) and 5-HT (Thomas et al., 1998) receptors. ODA does not 
belong to the NAEs family of ECs, but it has been demonstrated to bind to the 
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CB1 receptor in vitro (Leggett et al., 2004). However, whether it can be 
classified as an endogenous cannabinoid is still under debate (Fowler, 2004). 
Recently, it has been proposed to use the appellation of endocannabinoid-like 
molecules (ECLs) when referring to compounds such as OEA, PEA, ODA and 
other families of ECs related molecules (Alexander et al., 2007). 
 
1.2. ECs biochemistry 
1.2.1. Biosynthesis 
ECs biosynthesis can follow various pathways and it is believed to differ from 
that typical of classical neurotransmitters in which vesicle storage is involved. 
AEA and 2AG, and more in general all ECLs, exist as preformed precursors in 
the membrane and thus are enzymatically produced on-demand in response to 
specific signals, such as an increase in intracellular calcium or activation of 
phospholipase C ȕ by Gq/11 metabotropic receptors (Straiker et al., 2006). 
 
1.2.1.1. FAAs and AEA 
FAAs biosynthesis has been widely studied. Early work was done on PEA and 
OEA hydrolysis, while lately much attention has been given to AEA 
biosynthesis (Schmid, 2000). The major biosynthetic pathway involves a 
calcium-dependent transacylase that transfers an acyl group from the sn-1 
position of phospholipids to the N-position of phosphatidylethanolamine to 
form N-acyl-phosphatidylethanolamine (NAPE, Figure 1.3). A phospholipase 
D selective for NAPEs (NAPE-PLD) then hydrolyses them to form the 
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corresponding NAE (Bisogno et al., 2005; McKinney et al., 2005). The 
activity of NAPE-PLD is regulated by membrane depolarization or by a 
number of major neurotransmitters, such as dopamine, glutamate and 
acetylcholine (Giuffrida et al., 1999; Kim et al., 2002; Varma et al., 2001). It 
is worth mentioning that other pathways have also been proposed (Liu et al., 
2008) 
 
 
Figure 1.3: Proposed biosynthetic route for NAEs (Taken from McKinney and 
Cravatt, 2005) 
 
The fatty acid primary amides (FAPAs) and ODA biosynthetic pathway has 
been less intensively investigated, but is believed to involve the peptidyl 
glycine Į-amidating monooxygenase (PGAM). FAPAs may be generated by 
oxidative cleavage of N-fatty acyl glycines by PGAM (Figure 1.4) (McKinney 
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and Cravatt, 2005). Recently, Driscoll et al. (2007) suggested that cytochrome 
C may also be a route for ODA synthesis. 
 
 
Figure 1.4: Biosynthetic pathway for FAPAs (Taken from McKinney and 
Cravatt, 2005) 
 
1.2.1.2. 2AG 
In unstimulated tissues and cells the levels of the other main endogenous 
cannabinoid 2AG are higher than those of AEA (Sugiura et al., 1995) and its 
biosynthetic pathway follows a separate route from that of AEA. In most cases, 
2AG is produced from the hydrolysis of diacylglycerols containing 
arachidonate in the 2 position (DAGs), catalysed by a DAG lipase selective for 
the sn-1 position (Figure 1.5). Two sn-1 DAG lipase isozymes ('$*/ĮDQG
'$*/ȕ) have been cloned (Bisogno et al., 2003). DAGs, in turn, can be 
produced from the hydrolysis either of phosphoinositides (PI), catalysed by a 
PI-selective phospholipase C (PI-PLC), as in macrophages, platelets and 
cortical neurons, or of phosphatidic acid (PA), catalysed by a PA 
phosphohydrolase, in mouse neuroblastoma cells N18TG2 and in a rat 
microglial RTMGL1 cell line (Bisogno et al., 2005).  
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Figure 1.5: Biosynthetic pathways for the endocannabinoid 2- 
arachidonoylglycerol. PAH: phosphatidic acid hydrolase, PLC: phospholipase 
C.  
 
1.2.2. Catabolism  
Cessation of AEA and 2-AG signaling is believed to occur via a two-step 
process: transport of endocannabinoids from the extracellular to the 
intracellular space, and intracellular degradation by hydrolysis or oxidation. 
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1.2.2.1. Transport 
Although the majority of these models were developed based on data from 
AEA uptake studies, there is some evidence to suggest that AEA and 2-AG 
uptake occur via a common mechanism.  
 
 
Figure 1.6: Various proposed models for EC transport: 1) EMT: putative EC 
membrane transporter. 2) Passive diffusion and intracellular sequestration 
model. 3) FAAH/MGL driven passive diffusion. 4) Carrier-mediated caveolae-
Related endocytosis.  
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Various uptake mechanisms have been proposed in the recent years for both 
AEA and 2AG (Figure 1.6). The first model requires a yet to be cloned 
putative EC membrane transporter (EMT) assisting in the translocation of ECs 
across the plasma membrane. Another theory counts on ECs passively 
diffusing across the plasma membrane along a catabolism-driven concentration 
gradient. ECs are sequestered in an intracellular compartment or by binding to 
an intracellular binding protein prior to metabolism. Alternatively, ECs might 
passively diffuse across the plasma membrane along a concentration gradient 
that is driven by their rapid metabolism. Finally, ECs might be transported into 
cells via a protein carrier-mediated caveolae-related endocytic event (Yates et 
al., 2009). 
 
1.2.2.2. Hydrolysis 
FAAs and AEAs signalling is mainly terminated by the Fatty Acid Amide 
Hydrolase (FAAH, Figure 1.7), the major enzyme controlling their signalling 
and concentration in vivo. Early work on this enzyme was done on OEA 
hydrolysis in rat liver (Schmid et al., 1985). AEA was then showed to be 
hydrolysed by FAAH and the first inhibitor of this enzyme was discovered 
(Deutsch et al., 1993). FAAH is a member of an unusual class of serine 
hydrolases termed the amidase signature family that utilizes a serine-serine-
lysine catalytic triad (McKinney and Cravatt, 2005). FAAH enzyme activity is 
highest at alkaline pH and, amongst the FAAs, AEA seems to be the preferred 
substrate (McKinney and Cravatt, 2005). FAAH hydrolyses AEA to 
ethanolamine and arachidonic acid and this latter metabolite in particular has 
Endocannabinoid metabolism and PPARs signalling 
 
Introduction - 17 
 
been demonstrated to be involved at least in some of the AEA effects in mice 
in a tetrad of tests sensitive to ECs (Wiley, 2006). 
 
Figure 1.7: Mechanisms for endocannabinoids inactivation. FAAH: fatty acid 
amide hydrolase; MGL: monoacylglycerol lipase; EMT: putatitve EC 
membrane transporter.  
 
Recently, a second FAAH widely distributed in mammalian tissues and not 
expressed in rodents has been isolated and named FAAH-2. This enzyme 
works at alkaline pH but the preferred substrate seems to be ODA, a primary 
fatty acid amide (Wei et al., 2006). These two hydrolytic enzymes show a 
differential pattern of expression in human tissues, FAAH being mainly 
expressed in the brain, kidney, liver, small intestine, lung, prostate and testis 
while FAAH-2 being mostly found in the kidneys, liver, lung, prostate, heart 
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and ovaries (Table 1.2) (Wei et al., 2006). A third enzyme, N-
Acylethanolamine-hydrolizing Acid Amidase (NAAA) was recently 
discovered. NAAA works at a more acidic pH and PEA appears to be the 
major substrate for this enzyme (Tsuboi et al., 2005). 
 
FAAH FAAH-2 
Brain 
Kidney 
Liver 
Small intestine 
Lung 
Prostate 
Testis 
Heart 
Kidney 
Liver 
Lung 
Prostate 
Ovary 
 
Table 1.2: Tissue distribution of human FAAH and FAAH-2 RNA (Wei et al., 
2006) 
 
2AG, the other main endogenous cannabinoid, is mainly hydrolysed to 
glycerol and arachidonic acid by the enzyme monoglyceride lipase (MGL, 
Figure 1.7). MGL is a serine hydrolase and is unevenly present in the rat brain, 
with highest levels in regions where CB1 cannabinoid receptors are also 
expressed (hippocampus, cortex, anterior thalamus and cerebellum) (Dinh et 
al., 2002). However, 2AG has been previously showed to be hydrolysed also 
by FAAH under particular circumstances (Di Marzo et al., 2008). 
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1.2.2.3. Oxidation 
Because of their fatty acid chain, both AEA and 2AG can also be metabolised 
by the same enzymes that are responsible for arachidonic acid oxidation. COX-
2 is responsible for catalyzing the oxidation of AEA and 2AG into various 
prostaglandin-ethanolamides (or prostamides) and prostaglandin-glycerol 
esters, respectively (Fig. 1.8) (Yates et al., 2009) 
 
 
Figure 1.8: The major metabolites generated via COX-2-mediated oxidation 
of the endocannabinoids A) AEA and B) 2-AG. Prostaglandin E2 
ethanolamide, PGE2-EA; prostaglandin E2 glycerol esther, PGE2-GE. Taken 
from (Yates et al., 2009) 
 
12-LOX and 15-LOX have also been identified as enzymes metabolising both 
AEA and 2-AG in intact cells. Oxidative metabolism of AEA by 12-LOX and 
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15-LOX results respectively in the formation of 12- and 15 
hydroperoxyeicosatetraenoylethanolamide (12-HETE-EA and 15-HETE-EA), 
while 12-LOX- and 15-LOX-mediated oxidation of 2AG results in the 
formation of 12- and 15-hydroperoxyeicosatetraenoic acid glycerol ester (12 
HETE-GE and 15-HETE-GE), respectively (Figure 1.9) (Yates et al., 2009). 
Cytochrome P450 is also been shown to be involved in anandamide 
metabolism (Snider et al., 2009). 
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Figure 1.9: The major metabolites generated via oxidation of A) AEA and B) 
2-AG by the 12- and 15-LOXs. Hydroperoxyeicosatetraenoylethanolamide, 
HETE-EA; hydroperoxyeicosatetraenoic acid glycerol ester, HETE-GE. Taken 
from (Yates et al., 2009) 
 
1.2.3. FAAH inhibitors 
In the recent years, much attention has been given to the possibility of 
manipulating the endogenous cannabinoid system, and in particular FAAH 
enzyme activity, in order to augment the intracellular levels of the 
endocannabinoids and increase their activity. One of the most promising 
applications of this pharmacological modulation may be in the treatment of 
inflammatory pain (Fowler, 2006). Cannabinoids and endocannabinoids can 
indeed mediate antihyperalgesia and antinociception, but their mechanism of 
action is still poorly understood. Although the mechanism by which these 
compounds can evoke antinociception in the CNS seems to be mediated 
primarily by the CB1 receptors, the peripheral mechanism by which some 
cannabinoids mediate antihyperalgesia appears to be indirect or possibly 
involve non-CB1 or ±CB2 receptors (Patwardhan et al., 2006). FAAH is a 
promising drug target for pain treatment because it might allow the avoidance 
of undesirable central side effects associated with CB receptor activation 
(Table 1.3). For example, its pharmacological inhibition increases AEA levels 
in the brain without inducing immobility, hypothermia or over-eating at doses 
that are effective at abrogating pain (Kathuria et al., 2003; Piomelli et al., 
2006). FAAH knockout mice have higher levels of AEA in the brain and show 
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signs of an exaggerated endocannabinoid tone, such as reduced pain sensation 
(Cravatt et al., 2001). Various authors reported that FAAH inhibition is anti-
nociceptive in models of acute and inflammatory pain (Fegley et al., 2005; 
Holt et al., 2005; Kathuria et al., 2003; Russo et al., 2007). However, while 
FAAH inhibition consistently seems to reduce the response to acute and 
chronic inflammatory pain through an endocannabinoid related mechanism, its 
role in neuropathic pain is still unclear (Jhaveri et al., 2006). 
 
 
Table 1.3: Comparison of behavioral effects of CB1 agonists versus the 
JHQHWLF>JOREDOííRUSHULSKHUDO16@RUFKHPLFDOLQKLELWRULQDFWLYDWLRQRI
FAAH (Taken from McKinney and Cravatt, 2005) 
 
1.2.3.1. URB597 
URB597 (F\FORKH[\O FDUEDPLF DFLG ¶-carbamoyl-biphenyl-3-yl ester, Figure 
1.10) is a potent and selective FAAH and FAAH-2 inhibitor (Wei et al., 2006). 
It exhibits selectivity for FAAH compared to Monoacyl Glycerol lipase (MAG 
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lipase), the principal catabolic enzyme for 2-AG and has been shown not to 
bind to cannabinoid receptors (Kathuria et al., 2003). URB597 and related 
carbamate compound inhibit FAAH by covalent modification of the active site 
(Alexander et al., 2005). 
 
 
Fig 1.10: Chemical structure of URB597 (Taken Fegley et al., 2005) 
 
URB597 caused the augmentation of AEA, PEA and OEA levels in the brain 
of rats and wild-type mice but failed to have this effect in FAAH null mice 
(Fegley et al., 2005). It has also been demonstrated that URB597 dose-
dependently reduces oedema formation in carrageenan-induced hind paw 
inflammation by reducing FAAH activity (Holt et al., 2005).  
 
1.2.3.2. OL135 
OL135 is a Į-keto-heterocycle (Figure 1.11) that belongs to a potent and 
reversible class of FAAH inhibitors that show strong selectivity for FAAH 
relative to other mammalian hydrolases (Boger et al., 2005). As URB597, even 
OL135 has been proven to inhibit FAAH-2 (Wei et al., 2006). When 
administered to rodents, OL135 raise central nervous system levels of AEA 
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and promote cannabinoid receptor 1-dependent analgesia (Chang et al., 2006; 
Lichtman et al., 2004). Moreover, inhibition of FAAH by OL135 enhances the 
anti-allodynic actions of ECs in a mouse model of acute pain (Palmer et al., 
2008). 
 
 
Fig 1.11: Chemical structure of OL135. Taken from (Lichtman et al., 2004) 
 
1.2.3.3. PF-750 
Recently, both URB597 and OL135 have been demonstrated to have some off-
targets. Indeed, activity-based protein profiling (ABPP) and enzymatic assays 
showed that they can inhibit various carboxylesterases (Zhang et al., 2007). On 
the contrary, ABPP showed that PF-750 (N-phenyl-4-(quinolin-3-
ylmethyl)piperidine-1-carboxamide, Figure 1.12) was completely selective for 
FAAH relative to other mammalian serine hydrolases. PF750 belongs to a 
novel class of piperidine ureas irreversible FAAH inhibitors that show higher 
in vitro potencies than previously established classes of FAAH inhibitors (Ahn 
et al., 2007). 
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Fig 1.12: Chemical structure of PF-750. Taken from (Ahn et al., 2007) 
 
1.3. Peroxisome proliferator-activated receptors 
Recently, it has been demonstrated that ECs are not only ligands for the 
cannabinoid receptors. In fact, their activity cannot always be explained by the 
sole interaction with cannabinoid receptors and they have been demonstrated 
to modulate the activation of several other receptor types including opioid 
receptors, vanilloid TRPV1 receptor, serotonin (5-HT)3 receptor, N-methyl-D-
aspartate (NMDA) receptor, glycine receptors and nicotinic acetylcholine 
receptors (nAChR) (Demuth et al., 2006). Moreover, ECs modulate the 
functional properties of voltage-gated ion channels including Ca2+ channels, 
Na+ channels, various types of K+ channels (Oz, 2006). Recent findings have 
also highlighted the interaction of the endocannabinoid system and related 
compounds with the peroxisome proliferators-activated receptors PPARs 
(O'Sullivan, 2007). 
 
PPARs are nuclear hormone receptors. They act as ligand-activated 
transcription factors and they are principally linked to lipid metabolism, 
glucose homeostasis, apoptosis, immune response modulation and 
inflammation. There are three types of PPARs and they are all encoded by 
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GLIIHUHQW JHQHV 33$5Į LV PDLQO\ H[SUHVVHG LQ EURZQ DGLSRVH WLVVXH OLYHU
NLGQH\KHDUWDQGVNHOHWDOPXVFOH33$5ȖLVhighly expressed in adipose tissue 
but it is also expressed in other tissues like muscle, colon, kidney, pancreas and 
VSOHHQ 33$5ȕ also FDOOHG 33$5į LV DOPRVW XELTXLWRXV EXW LW LV PDUNHGO\
H[SUHVVHG LQ EUDLQ DGLSRVH WLVVXH DQG VNLQ 33$5Į LV WKH least selective in 
terms of ligand binding among the three receptors and its natural ligands are 
various saturated and unsaturated fatty acids. 33$5Ȗ LV WKH PRVW VHOHFWLYHRI
the PPARs. Fatty acids and eicosanoid derivatives can bind this receptor, but 
33$5Ȗ PDUNHGO\ SUHIHUV SRO\XQVDWXUDWHG IDWW\ DFLGV OLNH OLQROHLF DFLG
OLQROHQLFDFLGDQGDUDFKLGRQLFDFLG1DWXUDOOLJDQGVRI33$5ȕDUHprostacyclin 
and unsaturated fatty acids with a selectivity that is intermediate between that 
RI 33$5Ȗ DQG 33$5Į $PRQJ WKH V\QWKHWLF OLJDQGV 33$5Ȗ ligands 
thiazolidinediones like rosiglitazone are used in patients with type 2 diabetes 
while fibrates, 33$5Į ligands, are used to treat dislipidemia (Berger et al., 
2002).  
 
Until recently, it was believed that upon binding of a ligand to the ligand 
binding domain (LBD), the PPAR receptor changes its conformation and 
forms an heterodimer with retinoid X receptor (RXR, a nuclear receptor for 9-
cis-retinoic acid) (Michalik et al., 2006). However, it has been shown that in 
vivo a high percentage of PPARs and RXR receptors is associated even in the 
absence of ligand (Tudor et al., 2007). This complex binds to the DNA through 
WKH33$5¶VDNA binding domain (DBD) and act as a transcription factor. The 
DBD binds specific response elements (PPREs) located within the promoter 
regions of downstream genes. Presence of a number of co-repressors and co-
Endocannabinoid metabolism and PPARs signalling 
 
Introduction - 27 
 
activators can either stimulate or inhibit receptor-mediated gene expression 
(Michalik et al., 2006). Notably, it has been demonstrated that co-regulator 
recruitment more than DNA binding plays a crucial role in receptor mobility, 
suggesting that the transcriptional complexes are formed prior to promoter 
binding (Tudor et al., 2007).  
 
 
Figure 1.13: Schematic diagram of PPARs function as ligand-activated 
transcription factors  
 
1.3.1. ECs and PPARs 
Recent findings suggested an interaction of the endocannabinoid system and 
related compounds (NAEs) with the nuclear receptors PPARs. Indeed, various 
authors reported how a variety of ECs can bind to and activate PPARs when 
Endocannabinoid metabolism and PPARs signalling 
 
Introduction - 28 
 
administered exogenously (O'Sullivan, 2007). AEA has been previously 
reported WRWUDQVDFWLYDWHDQG ELQG WRERWK33$5ĮDQG33$5Ȗ (Bouaboula et 
al., 2005; Sun et al., 2006). 2AG was also demonstrated to transactivate both 
33$5Į DQG 33$5Ȗ (Kozak et al., 2002; Rockwell et al., 2006a). Moreover, 
the anti-inflammatory properties of PEA have been shown to be PPARĮ-
dependent in vitro and PEA stimulates PPARĮgene expression when topically 
applied to mouse skin (Lo Verme et al., 2005). It has also been proposed that 
2($ HOLFLWV VDWLHW\ LQ URGHQWV E\ DFWLYDWLQJ 33$5Į in the vagal nerve 
(Guzman et al., 2004). OEA also causes lipolysis in adipose tissue by a 
PPARĮ-dependent route (Guzman et al., 2004). Finally, THC and cannabidiol 
(CBD) have both been reported to elicit vasorelaxation through a PPARȖ 
dependent mechanism (O'Sullivan et al., 2009; O'Sullivan et al., 2005). 
 
Recently, in vivo effects of FAAH inhibition by URB597 such as analgesia, 
enhancement of memory acquisition and suppression of nicotine-induced 
excitation of dopamine cells have been linked to PPAR activation (Jhaveri et 
al., 2008; Mazzola et al., 2009; Melis et al., 2008). Growing interest has been 
given in recent years to the ability of PPARs to modulate neuroinflammation 
and neurodegeneration. PPAR signalling can have an important role in several 
diseases of the central nervous system, amongst them Multiple Sclerosis, 
3DUNLQVRQ¶V DQG $O]KHLPHU¶V GLVHDVH (Drew et al., 2006). In particular, 
activation of 33$5ȖLVWKRXJKWWRSOD\DQLPSRUWDQWUROHLn brain inflammatory 
conditions inhibiting the production of proinflammatory mediators like 
cytokines and inducible nitric oxide synthase (García-Bueno et al., 2005). 
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1.4. Aim of the study 
The aim of the present work was to dissect the mechanism by which inhibition 
of NAEs catabolism can modulate PPARs activation. The possibility of 
elevating intracellular levels of ECs by inhibiting their metabolism and 
whether this augmentation would lead to activation of PPARs nuclear 
receptors was tested (Figure 1.14). This issue was addressed by using the 
potent and selective FAAH inhibitor URB597 alongside OL135 and PF750, 
two structurally and functionally distinct FAAH inhibitors, to determine 
whether the intracellular elevation of FAA levels can lead to activation of 
PPARs nuclear receptors. Human neuroblastoma cells (SH-SY5Y) were used 
as a model of neuronal cells. HeLa cells, a cell line derived from a human 
cervical cancer, are widely used in the literature as a cell line lacking FAAH 
(Day et al., 2001) and were used in the present study as a negative control.  
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Figure 1.14: Schematic view of the hypothesis of the present study: 
pharmacological inhibition of FAAH should lead to an increase in intracellular 
ECLs that would in turn activate PPARs nuclear receptors. FA: fatty acid 
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2. MATERIALS AND METHODS 
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2.1. Materials 
2.1.1. Reagents 
All the reagents used in the study were purchased from Sigma (St. Louis, 
MO/USA), unless otherwise stated. AEA, 2-AG, OEA, PEA, arachidonic acid, 
palmitic acid, oleic acid, WY14643, GW0742, GW6471, GW9662 were 
purchased from Tocris Cookson (Bristol, UK). ODA was prepared by Dr 
Stephen Alexander by condensation of oleoylchloride with saturated ammonia 
solution and purification over silica. OL135 was a kind gift from Prof Ben 
Cravatt (San Diego, CA/USA). GSK0660 and rosiglitazone were donated by 
GlaxoSmithKline (London, UK). CCP was synthesised by Dr Stephen 
Alexander. Radiolabeled anandamide [ethanolamine-1-3H] ([3H]AEA, 
(specific activity 2.2x1012 Bq/mmol) and 2-mono-oleoylglycerol [glycerol-
1,2,3-3H] ([3H]2OG, specific activity 7.4x1011 Bq/mmol) were obtained from 
American Radiolabeled Chemicals (St. Louis, MO/USA). 
 
2.1.2. Enzymes and antibodies  
Molecular biology enzymes used in this study were all purchased from 
Promega (Madison, WI/USA) unless otherwise stated. Because of time 
limitations, a single protocol has been used for all antibodies used in the study. 
Rabbit polyclonal anti-FAAH antibody was from Millipore (Billerica, 
MA/USA); mouse monoclonal anti-PPARĮantibody was from Sigma (Poole, 
UK); rabbit polyclonal anti-33$5ȕ ZDV IURP 6DQWD &UX] 6DQWD &UX]
CA/USA), rabbit polyclonal anti-33$5Ȗ ZDV IURP &HOO 6LJQDOLQJ %HYHUO\
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MA/USA); mouse monoclonal anti-ɴ-actin and mouse polyclonal anti-actin 
were from Sigma (Poole, UK).  
 
2.1.3. Vectors and cell lines 
Name Origin Insert Length 
pcDNA3.1/Zeo-hPPARɲ Invitrogen 1.4 kbp 
pcDNA3.1/Zeo-hPPARɴ Invitrogen 1.3 kbp 
pcDNA3.1/Zeo-hPPARɶϮ Invitrogen 1.5 kbp 
 
Human neuroblastoma SH-SY5Y cells, human cervical adenocarcinoma HeLa 
cells, Chinese hamster ovary CHO cells and mouse embryonic fibroblast 3T3-
L1 cells were all purchased from ECACC (Salisbury, UK). 
 
2.2. qRT-PCR 
2.2.1. First strand cDNA synthesis 
Primers and probes for the target gene and for reference genes were designed 
using Primer Express 2 (Applied Biosystems, Foster City, CA/USA). A list of 
all primers and probes used in this study is available in Appendix. 
mRNA or total RNA was extracted with either the mRNA extraction kit 
(Invitrogen, Carlsbad, CA/USA) or RNA cleaning kit (QIAGEN, Valencia, 
CA/USA). Purified total/mRNA concentrations were detected with the 
NanoDrop spectrophotometer (Thermo scientific, Waltham, MA/USA). 
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Similar amounts of RNA (usually 1 ȝg total RNA or 100 ng mRNA) from 
different samples were then used as a template for RT-PCR synthesis of first 
strand cDNA using either M-MLV or SuperScript (Invitrogen, Carlsbad, 
&$86$ UHYHUVH WUDQVFULSWDVH DFFRUGLQJ WR WKH PDQXIDFWXUHU¶V SURWRFRO
Samples were then diluted 5 times with HPLC water. 
 
2.2.2. Relative Standard Curve Method 
Standard cDNA dilutions are required in order to quantify relative 
concentrations of the target and reference gene in the samples. Serial dilutions 
(4-fold) of either a mix of cDNA from different samples or cDNA from a 
tissue known to express the gene of interest were used as standard cDNA.  
Serial dilutions of the standard cDNA and a non-template control (NTC) were 
run in triplicate for both the reference and the target gene in order to construct 
two standard curves. A master mix was prepared for both the reference gene 
and the target gene using TaqMan Rox-UDG mix (Applied Biosystems, Foster 
City, CA/USA DFFRUGLQJ WR WKH PDQXIDFWXUHU¶V SURWRFRO 6DPSOHV ZHUH
loaded into a 96-well plate (Applied Biosystems, Foster City, CA/USA) and 
the final reaction volume was 25 µL. The plate was sealed with transparent 
film (Applied Biosystems, Foster City, CA/USA) and the qRT-PCR reaction 
was then carried out in a 7700 detection system (Applied Biosystems, Foster 
City, CA/USA). 
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2.3. Protein quantitation 
2.3.1. Bradford Method 
Bradford protein determination was carried out using the Bio-Rad (Hercules, 
CA/USA) Protein Assay Dye Reagent Concentrate according to the 
PDQXIDFWXUHU¶VSURWRFRO 
 
2.3.2. BCA Method 
Bicinchoninic acid (BCA) protein determination was carried out using the 
Thermo scientific (Waltham, MA/USA) BCA Protein Assay Reagent 
DFFRUGLQJWRWKHPDQXIDFWXUHU¶VSURWRFRO 
 
2.3.3. SDS polyacrylamide gel electrophoresis and 
immunoblot 
The procedure was essentially as described by (Laemmli, 1970) and carried out 
using 10 % slab gels in Bio-Rad Minigel System (Hercules, CA/USA). Gels 
were run at 100 mA until the dye front reached the bottom of the gel. Gels 
were then removed from the glass plates and proteins were transferred to a 
nitrocellulose membrane (Hybond, Escondido, CA/USA) by electrophoresis at 
200 mA for 1 hour. The membrane was incubated in 5 % (w/v) non-fat dried 
milk Marvel (Cadbury, London, UK) in phosphate buffered saline (PBS) for 1 
hour at room temperature. The membrane was then incubated overnight at 4 ºC 
with primary antibody in 5 % (w/v) Marvel in PBS Tween (0.1 % v/v). The 
membrane was rinsed three times followed by a further four 20 minute washes 
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in PBS Tween. The membrane was incubated for 1 hour with the appropriate 
secondary antibody in 1 % (w/v) Marvel, PBS Tween (0.1 % v/v). The 
membrane was rinsed three times followed by four 20 minutes washes in PBS 
Tween and a further wash of 10 minutes in dH2O. The membrane was either 
developed using the Amersham ECL Western blotting detection system (GE 
Healthcare Life Sciences, Uppsala, Sweden) or transferred to an Odyssey 
scanner (LI-COR Biosciences, Lincoln, NE/USA) according to the 
PDQXIDFWXUHU¶VSURWRFRO 
 
2.4. Enzymatic activity 
2.4.1.  [3H]-AEA hydrolysis Ȃ Cell homogenate 
Incubation buffer: Hanks/Hepes buffer: NaCl 116 mM, KCl 5.4 mM, CaCl2·2H2O 1.8 
mM, HEPES 25 mM, MgSO4 0.8mM, NaH2PO4·2 H2O 1 mM, supplemented with 1 
mg/ml defatted bovine albumin serum from Sigma, pH 7.4 
 
This method is based on the hydrolysis of AEA tritiated in the ethanolamide 
moiety ([3H]-AEA) adapted from (Holt et al., 2005) and (Boldrup et al., 2004). 
Cell pellets (-80 °C) from 75 cm2 flasks were thawed and re-suspended in 50 
ȝL homogenising buffer (50 mM Tris, 1 mM EDTA, 5 mM MgSO4, pH 7.4). 
Samples were then sonicated on ice in two 5 seconds burst to avoid over-
heating. Fifty ȝL RIKRPRJHQDWHZDVGLOXWHGLQȝL incubation buffer. 
$  ȝL DOLTXRW ZDV SUH LQFXEDWHG ZLWK 85%  ȝ0 LQ Dimethyl 
sulfoxide, DMSO). The DMSO concentration did not exceed 1 % (v/v). The 
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UHPDLQLQJȝL DOLTXRWDQGWKHȝL aliquot were incubated at 37 °C for 
30 min. 200 ȝ/ aliquots of pre-incubated homogenates were then further 
incubated for 30 min at 37 °C in 1.5 mL Eppendorf tubes with [3H]-AEA (2 
ȝ0 final AEA concentration, spiked with 1% [3H]-AEA). 
0.4 mL activated charcoal (4 % w/v in 0.5 M HCl) was then added and the 
PL[WXUH ZDV FHQWULIXJHG DW  USP IRU  PLQV  ȝL aliquots of 
supernatant layerswere then added to 3.5 ml scintillation fluid (Emulsifier-
Safe, PerkinElmer, Waltham, CA/USA) and counted for [3H] (minimum of 3 
min) with quench correction using a scintillation analyzer (Tri-Carb, 
PACKARD, Palo Alto, CA/USA). The protein content of homogenates 
(mg/mL) was determined by Bradford methods (see Section 3.1). Activity was 
expressed in pmoles/(min x mg protein). 
 
2.4.2.  [3H]-AEA/ [3H]-2OG hydrolysis Ȃ Intact cells 
Washing buffer: Hanks/Hepes buffer: NaCl 116 mM, KCl 5.4 mM, CaCl2·2H2O 1.8 
mM, HEPES 25 mM, MgSO4 0.8mM, NaH2PO4·2H2O 1 mM, pH 7.4 
Incubation buffer: Washing buffer supplemented with 1 mg/ml defatted bovine 
albumin serum from Sigma. 
 
This method is based on the hydrolysis of either AEA tritiated in the 
ethanolamide moiety ([3H]-AEA) or 2OG tritiated in the glycerol moiety ([3H]-
2OG, adapted from (Holt et al., 2005). Cells were seeded on the day before the 
experiment in 24-well plates at a density of 2x105 cells/well in complete 
growth medium and placed in the incubator at 37 ºC and 5 % CO2 overnight. 
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Cells were then treated with the appropriate compound in complete growth 
medium for the indicated time. DMSO concentration never exceeded 0.1%. 
After the treatment, cells were incubated at 37 ºC for the rest of the 
experiment. Cells were washed with washing buffer. Incubation buffer was 
then added to the wells. In experiments with pre-incubation treatment, the 
appropriate compound was added to a final volume of 350 µL and cells were 
incubated at 37 °C for 15 minutes. [3H]-AEA or [3H]-2OG (8 ȝ0 VROXWLRQ
was prepared by adding 0.8 ȝL [3H]-AEA or [3H]-2OG respectively, per each 
2 mL of solution. The appropriate tritiated compound was then added to the 
cells to a final concentration of 2 µM and a final volume of 400 µL. Cells were 
incubated at 37 ºC for 10 minutes and the reaction was stopped by placing 
them on ice for the rest of the experiment. Cells were washed and 400 µl of 
ice-cold methanol was added. Cells were scraped and the suspension was 
transferred to Eppendorf tubes where 400 µL of chloroform and 200 µL of 
H2O were added. Samples were vortexed and centrifuged at 13000 rpm for 5 
minutes. 300 µL aliquots of the liquid upper phase were then added to 3 mL of 
scintillation fluid Emulsifier-Safe (PerkinElmer, Waltham, MA/USA) and 
counted for [3H] with a long count (minimum of 3 min) using a scintillation 
analyzer (Tri-Carb, PACKARD, Palo Alto, CA/USA). Tissue blanks were 
measured in empty wells following the same procedure described so far. 
Standards were measured in triplicates by adding the tritiated compound 
directly to 3 mL of scintillation fluid. Activity was expressed in pmoles/(min x 
well). 
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2.4.3. ODA hydrolysis Ȃ Cell Homogenate 
Phosphate buffer/EDTA (NaH2PO4 5.92g/l, Na2HPO4 28g/l, EDTA 370g/l, pH=7.4) 
Potassium phosphate solution: K3PO4 42g/l and K2HPO4 34g/l 
OPA/sulphite: OPA 0.65g/l and Na2SO3 0.85 g/l 
 
Cells were grown to confluence and collected with 5 mM EDTA in PBS. The 
cell pellet was re-suspended in phosphate buffer/EDTA (pH 7.4) and 
homogenised by sonication. The suspension was then spun at 30 000 g for 15 
minutes and the resultant particulate preparation was re-suspended in 
phosphate buffer/EDTA (pH 7.4) and homogenised by sonication. Ammonia 
was then determined in the presence of excess ortho-phthalaldehyde (Ahn et 
al.) and sulphite following an adaptation from (Mana et al., 2001). 
Homogenate was incubated at 37 °C for 30 minutes together with ODA (100 
µM) and either URB597 (1 µM) or DMSO (5 %). Tissue blanks were 
incubated alongside. Substrate blanks were prepared by adding ODA (100 µM) 
after the incubation. The reaction was stopped by putting the sample on ice and 
adding trichloroacetic acid to a final concentration of 1 % (w/v). After 
centrifugation at 5000 g for 5 minutes, aliquots of deproteinised supernatant 
layer were dispensed into a 96-well microtitre plate together with 2 volumes of 
OPA/sulphite in potassium phosphate solution, pH 11.5. Reaction was allowed 
to run for 30 minutes and fluorescence was read at 390nm excitation 460nm 
emission. Standards were obtained by adding 2 volumes of OPA/sulphite 
solution to 16 µmol (NH4)2SO3 in phosphate/EDTA buffer. Hydrolysis rate 
was expressed as nmoles/min/mg protein.  
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2.5. RNA interference 
2.5.1. miRNA 
Cells were seeded the day before transfection in 6-well plates in order to reach 
a confluency of 80-90 % on the day of transfection. Four separate miRNA 
constructs (Invitrogen, Carlsbad, CA/USA: two constructs against FAAH, two 
individual preparations each) were transfected with TransFast transfection 
reagent (Promega, Madison, WI/USA) DFFRUGLQJ WR WKH PDQXIDFWXUHUV¶
instructions. Cells were harvested after 24 hours and mRNA was extracted 
with mRNA extraction kit (Invitrogen, Carlsbad, CA/USA). 
 
2.5.2. siRNA 
2.5.2.1. Electroporation 
Cells were passaged three days before transfection and grown to around 80 % 
confluency in T75 flasks. siRNAs (Ambion, Austin, TX/USA ) were delivered 
by electroporation with Nucleofector (Amaxa, Germany). Cells were 
nucleofected in suspension and subsequently plated in 6-well dishes with 
complete culture medium. 
A positive construct against ɴ-actin and a mix of the best two constructs out of 
three preliminarily tested against FAAH were used. Cells were harvested after 
48 hours and total RNA was extracted with RNeasy columns (QIAGEN, 
Valencia, CA/USA). 
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2.5.2.2. Transfection 
Cells were seeded in 24-well plates to reach around 25 % confluency on the 
day of transfection. siRNAs (Dharmacon, Lafayette, CO/USA) were delivered 
with Dharmacon modified medium.  
A positive control against GAPDH, four individual constructs and a SmartPool 
of the four constructs were tested. Total RNA was extracted after 72 hours 
with RNeasy columns (QIAGEN, Valencia, CA/USA). 
 
2.5.3. shRNA 
Cells were seeded in 24-well plates in order to reach around 50 % of 
confluency on the day of transduction. Cells were treated with the viral 
particles (Sigma, Poole, UK) overnight. 
A positive control against beta 2-microglobulin gene (B2M) and five 
individual constructs (both at Multiplicity of Infection MOI=1 and MOI=3) 
were tested. Total RNA was extracted after 48 hours directly on the plates with 
Nano-scale RNA purification kit. 
 
2.6. Neutral Red Assay 
Destain solution: 50% ethanol, 49% dH2O, 1% glacial acetic acid, V/V 
 
A neutral red uptake was performed in intact cells following a protocol adapted 
from Repetto et al., 2008. On the day before the experiment, cells were seeded 
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in 24-well plates at a density of 2x105 cells/well in 1 ml of medium and placed 
in the incubator at 37 ºC and 5 % CO2 overnight. Cells were then treated with 
increasing concentrations of the appropriate compound in complete growth 
medium. As a positive control, cells were treated with saponin 0.1%, or vehicle 
(DMSO 0.3%) as a negative control.  
After 24 hours incubation, cells were quickly washed with PBS and medium 
was replaced with a solution of neutral red in 1 ml growth medium (33 mg/ml, 
no additives). Cells were then incubated for 3 hours at 37 ºC and 5 % CO2. 
Neutral red medium was then removed and cells were washed again with PBS. 
1 ml of destain solution was then added to the cells and the plate was shaken 
for 10 minutes. Aliquots of 100 µl were then dispensed to a 96-well plate in 
triplicates and absorbance was read at 550 nm.  
 
2.7. LC-MS/MS endocannabinoid measurement 
A liquid chromatography-tandem electrospray ionisation mass spectrometry 
(LC-MS/MS) method was employed for measurement of endocannabinoids 
(ECs) in cells by Dr Leonie Norris in the School of Pharmacy (University of 
Nottingham). In brief, lipids were extracted using ice cold acetonitrile with 
internal standards (0.42 nmol d8-AEA, 1.5 nmol d8-2-AG) based on the 
method of Richardson et al. (2007). Simultaneous measurement of ECs and 
related compounds was then performed using LC-MS/MS. Chromatographic 
separation was carried out on an Shimadzu system (Shimadzu, Milton Keynes, 
UK) using a Thermo Hypersil-Keystone BDS C18 (150 x 1 mm internal 
diameter, 5 µm particle size; Thermo Fisher Scientific, Runcorn, UK) with a 
Endocannabinoid metabolism and PPARs signalling 
 
Materials and Methods - 43 
 
mobile phase flow rate of 0.15 ml/min. Gradient elution chromatography with 
mobile phases consisting of A (water, 1 g/L ammonium acetate, 0.1% formic 
acid) and B (acetonitrile, 1 g/L ammonium acetate, 0.1% formic acid) was used 
over the range 15% B to 100% B. Samples were injected from a cooled auto 
sampler maintained at 4oC. Mass spectrometry detection used a 4000 QTRAP 
MS (Applied Biosystems, California, USA) in electrospray positive mode with 
multiple reaction monitoring of specific precursor and product mass to charge 
(m/z) ratios of AEA, 2-AG, PEA and OEA.  
 
Cells in each sample were counted with a haemocytometer and data are 
expressed as pmol/105 cells. 
 
2.8. Calcium mobilization  
Loading buffer: HBSS (MgCl2 1 mM, CaCl2 0.1 mM) with 5 mM glucose and 
0.1% BSA 
 
Cells were seeded in 96-well plates the day before the experiment in order to 
reach confluency close to 100 %. The measurements were carried out with the 
calcium-sensitive dye Fluo-4 (Invitrogen, Carlsbad, CA/USA) according to the 
vendor¶V instructions. Some adjustments to the original protocol were required 
to avoid the washing step after addition of the dye. The loading buffer was 
HBSS with glucose and BSA rather than media and FBS, as serum contains 
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different factors which would stimulate calcium release. 1 mM Brilliant Black 
was added to the loading buffer in order to quench the background 
fluorescence. The organic anion-transport inhibitor probenecid (2.5 mM) was 
added to reduce leakage of the de-esterified indicator.  
Fluo-4 was solubilised in 10 % pluronic acid in DMSO (1 mM stock solution). 
This non-ionic detergent assists in dispersion of the non-polar acetoxymethyl 
(AM) ester in aqueous media. The stock solution was diluted to 2 µM in 
loading buffer and added to the cells in a volume of 100 µl/well. Cells were 
incubated at 37 °C for 30 minutes.  
Drugs were prepared in loading buffer at the required concentrations. DMSO 
concentration never exceeded 0.1%. Fluorescence was read using a 96-well 
Flexstation (Molecular Devices, Sunnyvale, CA/USA). Data are expressed as 
percentage of the carbachol response (Peak-trough interval), with the vehicle 
control set as 0 %.  
 
2.9. Molecular biology methods 
2.9.1. Preparation and transformation of competent E. 
Coli 
LB medium: 10g tryptone, 5g yeast extract, 10g NaCl per litre 
 
A single bacterial colony was picked from a plate that was incubated for 16-20 
hours at 37 ºC and the colony was inoculated into 100 mL LB medium in a 1-
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litre flask. The culture was incubated at 37 ºC for 3 hours with vigorous 
agitation. The bacterial cells were transferred into sterile, ice-cold 50 mL 
polypropylene tubes. The cells were recovered by centrifugation at 2700 g for 
10 minutes at 4 ºC. The medium was decanted and the cell pellets were 
resuspended in 30 mL ice-cold 0.1 M sterile CaCl2 solution and recovered by 
centrifugation. The cells were washed in CaCl2 solution two more times as 
previously described. The cell pellets were then re-suspended in 2 ml CaCl2 
solution containing 12 % (v/v) DMSO and kept on ice for 1 hour before 
aliquoting and freezing at -80 ºC. For transformation, 100 ng DNA was added 
to 200 µL thawed competent cells. The mixture was stored on ice for 30 
minutes. LB medium (800 µL) was added to each tube and the cells were 
incubated for 1 hour with shaking at 37 ºC to allow the bacteria to express the 
antibiotic resistance marker encoded by the plasmid. Transformed competent 
cells were spread onto LB agar plates containing the appropriate antibiotic. 
The plates were incubated at 37 ºC until the transformed colonies appeared 
(15-20 hours).  
 
2.9.2. Plasmid DNA Maxi-Prep 
All Maxi-preps of plasmid DNA were carried out using Plasmid Maxi Kit 
(QIAGEN, Valencia, CA/USA) DFFRUGLQJWRPDQXIDFWXUHU¶VSURWRFRO 
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2.10. PPAR transactivation assay 
A luciferase reporter construct under the control of 3xPPRE was transfected 
into SH-SY5Y, HeLa and CHO cells either alone or together with a pcDNA3.1 
plasmid expressing the human PPARɲ, PPARɴ or 33$5ȖJHQHSH-SH5Y and 
HeLa cells were transiently transfected using TransFast transfection reagent 
(Promega, Madison, WI/USA) according to the manufacturer¶V instructions. 
Cells were transfected in 6-well plates with 1 µg luciferase plasmid and 1 µg 
PPAR expressing plasmid per well with a 1:1 DNA:reagent ratio. Transient 
transfection of CHO cells was carried out by the polyethyleneimine method 
with the ratio nitrogen (N) to DNA phosphate (P) of N/P=15 as previously 
described (Sun et al., 2007) 1 hour after transfection, HeLa cells were treated 
with the appropriate compounds while CHO cells were treated 4 hours after 
transfection. DMSO concentrations never exceeded 0.1%. 
Twenty-four hours after treatment, cells were harvested and lysed with Passive 
Lysis Buffer (Promega, Madison, WI/USA) and luciferase expression was 
monitored using the Luciferase Assay System (Promega, Madison, WI/USA) 
and a luminometer (TD-20/20, Turner Biosystems, Sunnyvale, CA/USA). Data 
were expressed as Relative Luciferase Units (RLU)/mg protein. 
 
2.11. PPAR ligand binding 
2.11.1. Ƚ 
To assess the binding properties of URB597, displacement of cis-parinaric acid 
(CPA) from mPPARɲ LBD was monitored by measuring the fluorescence of 
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CPA (Causevic et al., 1999). Purified mPPARɲ LBD protein was diluted to 1 
µM in TBS buffer; diluted proteins were mixed with 2 µM CPA from 
concentrated stock solution in ethanol, followed by addition of potential 
ligands from concentrated stock solutions in either DMSO or ethanol. Protein-
CPA-ligand mixtures (330 µL/well) were loaded into 96-well solid black 
microplates (Fisher Scientific, Loughborough, Leicestershire, UK). 
Fluorescence (excitation: 315 nm; emission: 415 nm) emission spectra were 
obtained by reading the plate from above using a Flexstation® II (Molecular 
Devices, Sunnyvale, CA/USA) at 25 ºC and corrected for background 
(fluorescent ligand only). The displacement of bound fluorescent ligand was 
calculated from the decrease in CPA fluorescence intensity with increasing 
concentrations of non-fluorescent ligand. Displacement curves were analyzed 
by fitting a curve to the data using a one-site competition binding model 
(Prism, GraphPad software, La Jolla, CA/USA).  
 
Binding experiments for ODA were carried out with LanthaScreenTM PPARĮ 
Competitor Assay (Invitrogen, Carlsbad, CA/USA) following the 
manufacturer¶V instructions. Black 384-well plates (Nunc, Denmark) were read 
with EnVision multilabel plate reader (PerkinElmer, Waltham, CA/USA). Data 
are calculated as emission ratio 520 nm/495 nm and reported as percentage of 
control. Displacement curves were analyzed by fitting a curve to the data using 
a one-site competition binding model (Prism, GraphPad software, La Jolla, 
CA/USA). 
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2.11.2. Ⱦ 
Binding experiments were carried out with LanthaScreenTM PPARȕ 
Competitor Assay (Invitrogen, Carlsbad, CA/USA) following the 
manufacturer¶V instructions. Black 384-well plates (Nunc, Denmark) were read 
with EnVision multilabel plate reader (PerkinElmer, Waltham, CA/USA). Data 
are calculated as emission ratio 520 nm/495 nm and reported as percentage of 
control. Displacement curves were analyzed by fitting a curve to the data using 
a one-site competition binding model (Prism, GraphPad software, La Jolla, 
CA/USA). 
 
2.11.3. ɀ 
Binding experiments were carried out with PolarscreenTM PPARȖ Competitor 
Assay Green (Invitrogen, Carlsbad, CA/USA) following the manufacturer¶V 
instructions. Black 384-well plates (Nunc, Denmark) were read with EnVision 
multilabel plate reader (PerkinElmer, Waltham, CA/USA). Data are reported 
as a percentage of the internal control. Displacement curves were analyzed by 
fitting curves to the data using a one-site competition binding model (Prism, 
GraphPad software, La Jolla, CA/USA). 
 
2.12. 3T3-L1 adipocyte differentiation  
3T3-L1 cells were grown to confluence in 6-well plates. 48 hours after 
FRQIOXHQFH WKH FXOWXUH PHGLXP ZDV UHSODFHG DQG VXSSOHPHQWHG ZLWK  ȝ0
GH[DPHWKDVRQHDQGȝJP/LQVXOLQ$IWHUKRXUVWKHFXOWXUHPHGLXPZDV
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UHSODFHGDQGVXSSOHPHQWHGZLWKȝJP/LQVXOLQ 6LJPD, Poole, UK) and the 
SXWDWLYH 33$5Ȗ OLJDQG &HOOV ZHUH JURZQ IRU DURXQG  GD\V FKHFNLQJ IRU
differentiation and changing the medium 2-3 times per week. Once 
differentiation occurred, cells were treated for 10 minutes with 4 % formalin 
and inoculated with Oil Red O at room temperature for 1 hour. Pictures of the 
wells were taken from the bottom of the wells with a scanner (Epson, Long 
Beach, CA/USA). 
 
2.13. Statistical analysis 
Statistical differences among treatments were calculated with Prism (GraphPad 
software, La Jolla, CA/USA), one-ZD\ $129$ ZLWK %RQIHUURQL¶s PostHoc 
test or two-tailed 6WXGHQW¶VW-test were applied where appropriate. 
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3. CELL LINE 
CHARACTERIZATION 
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3.1. Introduction 
The aim of this study was to check the expression in SH-SY5Y human 
neuroblastoma and HeLa human carcinoma cells of the various proteins that 
characterize the endocannabinoid machinery, together with expression of the 
three different PPARs isotypes. mRNA levels of the biosynthetic enzymes 
NAPE-PLD and DAGLɲ, the hydrolysing enzymes FAAH-1/2, NAAA and 
MGL, as well as the CB1 and CB2 receptors were monitored in these cell lines 
together ZLWK33$5Į33$5ȕDQG33$5Ȗ. In order to validate the assay, RNA 
extracted from tissues known to express the target gene at high levels (human 
brain, spleen or liver, see Table 3.1) were compared. Expression of PPARs and 
FAAH was then confirmed at the protein level by Western Blotting.  
 
In order to assess the capability of the cell lines used in the study to break 
down endocannabinoids, hydrolysis of AEA and ODA was monitored in cell 
homogenates using rat liver as a positive control.  
 
3.1.1. qRT-PCR 
qRT-PCR is based on the 5' exo-nuclease activity of Taq polymerase. This 
activity leads to break down of a probe labelled with a fluorescent (FAM) and 
a quencher (TAMRA) tag and subsequent increase in the signal at the 
wavelength specific for the fluorophore. Primers and probe were designed with 
Primer Express II (Applied Biosystems); software that allows the design of 
effective primers and probe pairs. The amplicon (PCR product) or, ideally, the 
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probe was designed to span an intron-exon boundary in order to avoid the 
amplification of a false positive product from genomic DNA. Selectivity of 
both primers and probes was checked by aligning the sequences to the human 
transcriptome with BLAST N (NCBI). 
 
Serial dilutions of a standard cDNA are required in order to construct a 
standard curve for each primers-probe pair following the ³5HODWLYH 6WDQGDUG
&XUYHV´ method. The slope of these curves is directly related to the PCR 
efficiency of each reaction. Comparable PCR efficiencies give the possibility 
of comparing relative expression of different genes. A mix of cDNAs from 
different samples was used as a standard in this study. Dilutions of the standard 
and the samples needed to be determined empirically. As a starting point, a 4-
IROGVHULDOGLOXWLRQRIWKHF'1$PL[ZDVXVHGIRUWKHȕ-actin (reference gene) 
standard curve while the samples were diluted five times. Results were 
interpolated from the reference gene standard curve, normalised to the 
reference gene expression and compared in terms of relative expression of each 
target gene. 
 
3.1.2. Western Blotting 
In this study, a polyclonal rabbit anti-FAAH antibody (Millipore) was used. 
This antibody recognized a 17 amino acid peptide sequence near the N-
terminus of human FAAH. Working concentration for this antibody was 5 
µg/ml (1/200 dilution). A monoclonal anti-33$5ĮDQWLERG\6LJPDUDLVHGLQ
mice with a synthetic peptide corresponding to AA residues 1-18 of mouse 
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33$5ĮPLVPDWFKZLWKKXPDQ33$5Į was used at a working concentration 
of 2 µg/ml (1/500). Rabbit polyclonal Anti-33$5ȕ DQWLERG\ Santa Cruz) 
recognised AA sequence 2-75 at the N-WHUPLQXV RI KXPDQ 33$5ȕ DQG WKH
working concentration was 2 µg/ml (1/100). The polyclonal antibody against 
33$5ȖZDVUDLVHGLQUDEELW&HOO6LJQDOLQJDQGUHFRJQLVHGDVHTXHQFHDURXQG
$VSRIKXPDQ33$5ȖWorking dilution for this antibody was 1/1000.  
 
3.1.3. Enzymatic assays 
In order to check the capability of the cells to break down endocannabinoids, 
two separate enzymatic assays were performed. The first one was a 
radioactivity based assay that exploits the hydrophilic properties of the tritiated 
ethanolamine moiety released from hydrolysis of tritiated AEA. Separation of 
product from the substrate was achieved with activated charcoal (Boldrup et 
al., 2004). This avoids the use of toxic solvents such as methanol and 
chloroform. The second enzymatic assay carried out in this study measured 
hydrolysis of ODA, a preferred FAAH-2 substrate (Wei et al., 2006). This 
assay monitors ammonia liberation from ODA hydrolysis, exploiting the 
fluorescent product of the reaction between ammonia and OPA (Mana et al., 
2001).  
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3.2. Results 
3.2.1. Endocannabinoid system 
3.2.1.1. RNA expression 
RNA levels of both NAPE-PLD and DAGLɲ͕ the two endocannabinoid 
synthetic enzymes, were relatively high in SH-SY5Y cells compared to HeLa 
cells (Table 3.1). FAAH expression was again much higher in neuroblastoma 
cells compared to HeLa cells, while FAAH-2 RNA was not detected in SH-
SY5Y and moderately expressed in HeLa cells. The two other catabolic 
enzymes monitored in this study, NAAA and MGL, were expressed in both 
cell lines with HeLa cells showing the higher RNA levels for these genes. The 
situation was inverted for CB1 and CB2 RNA expression. These receptors were 
indeed expressed in both cells but the neuroblastoma showed the highest RNA 
levels (Table 3.1). 
 
3.2.1.2. Protein expression 
Expression of the endocannabinoid hydrolysing enzyme FAAH was confirmed 
by Western blotting. The expected size for the FAAH protein was 63 kDa. SH-
SY5Y neuroblastoma cells showed a clear band just below 64 kDa while HeLa 
cells showed only a faint band at this size (Figure 3.1).  
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ȀȾ-actin 
(a.u.) 
SH-SY5Y  HeLa 
 
Positive control 
 
Tissue 
NAPE-PLD 1.80E-04 
±1.90E-05 
3.49E-05 
±2.57E-06 
5.92E-04 
±4.37E-05 
Human 
Brain 
Ƚ 1.23E-03 
±3.11E-04 
4.14E-04 
±5.66E-05 
6.10E-03 
±1.35E-03 
Human 
Brain 
FAAH 2.53E-03 
±1.35E-04 
1.44E-04 
±1.74E-05 
1.83E-02 
±1.24E-03 
Human 
Brain 
FAAH-2 Undetermined 4.01E-04 
±5.77E-05 
1.40E-03 
±8.88E-05 
Human 
Liver 
NAAA 6.69E-05 
±1.51E-05 
3.44E-04 
±4.58E-05 
9.65E-03 
±2.44E-04 
Human 
Liver 
MGL 3.73E-05 
±1.83E-06 
5.60E-04 
±8.77E-05 
2.60E-02 
±6.15E-03 
Human 
Brain 
CB1 8.15E-04 
±4.14E-05 
2.11E-05 
±3.40E-06 
3.53E-02 
±4.03E-03 
Human 
Brain 
CB2 3.34E-04 
±3.90E-05 
2.68E-05 
±6.87E-06 
1.18E-02 
±1.39E-03 
Human 
Spleen 
 
Table 3.1: qRT-PCR analysis of RNA expression in SH-SY5Y cells. Results 
are expressed as average arbitrar\ XQLWV QRUPDOLVHG E\ ȕ-actin and were 
conducted in triplicate. mRNA or total RNA was extracted from SH-SY5Y or 
HeLa cells and either human liver, spleen or brain as a positive control.  
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     (1)            (2) 
Figure 3.1: Western blotting of either 30 µg SH-SHY5Y (lane 1) or 30 µg 
HeLa (lane 2) protein using antibodies against FAAH (Millipore). The 
membrane was developed using the ECL Western blotting detection system 
(Amersham). The lane on the right molecular represents molecular weight 
markers (SeeBlue Plus2 ladder, Invitrogen) 
 
3.2.1.3. Activity assay 
3.2.1.3.1. [3H]-AEA Hydrolysis 
In a radioactivity based assay, SH-SY5Y cells were able to hydrolyse 
exogenously administered AEA. This activity was almost completely reversed 
by pre-incubation with the FAAH inhibitor URB597 (1 µM, P<0.05, Figure 
3.2). By contrast, HeLa cells showed no measurable AEA hydrolysis activity 
with or without URB597 pre-incubation. In the same assay, URB597 was able 
148 kDa 
98 kDa 
64 kDa 
50 kDa 
36 kDa 
22 kDa 
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to completely reverse AEA hydrolysis in rat liver microsomes (P<0.01, Figure 
3.2).  
 
 
Fig 3.2: AEA hydrolysis measured in particulate preparations from either SH-
SY5Y or HeLa cells or rat liver microsomes as a positive control. Samples 
were pre-incubated for 30 minutes with either DMSO (n=at least 6) as a 
control or URB597 1 µM (n> 3, * P<0.05, ** P<0.01, uQSDLUHG 6WXGHQW¶V W-
test, two-tailed, compared to control) 
 
3.2.1.3.2. ODA Hydrolysis 
Monitoring of ODA hydrolysis showed measurable activity in both SH-SY5Y 
and HeLa cells. In both cases, pre-incubation with URB597 almost completely 
inhibited ODA hydrolysis (P<0.05, Figure 3.3). In the same experiment, 
URB597 was able to inhibit ODA hydrolysis in rat liver microsomes, albeit 
only partially.  
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Fig 3.3: ODA hydrolysis measured in particulate preparations from either SH-
SY5Y or HeLa cells, or rat liver microsomes as a positive control. Samples 
were pre-incubated for 10 minutes with either DMSO as a control or URB597 
(1 µM, n=6, * P<0.05, *** P<0.001, uQSDLUHG 6WXGHQW¶V W-test, two-tailed, 
compared to control). 
 
3.2.2. PPAR expression 
Expression of the three PPAR isotypes was measured in neuroblastoma and 
HeLa cells, both at the RNA level by qRT-PCR and at the protein level by 
Western blotting. 
 
3.2.2.1. RNA expression 
Analysis of mRNA levels of the three PPAR isotypes from SH-SY5Y and 
HeLa cells revealed a similar pattern of relative expression in the two cell lines 
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(Table 3.2) ,Q QHXUREODVWRPD FHOOV 33$5ȕ ZDV WKH PRVW DEXQGDQW LVRW\SH
33$5Į was expressed at lower levels in these cells ZKLOH 33$5Ȗ RNA was 
almost undetected. The expression relative to 33$5Ȗ was: 33$5ȕ (11600-
fold) > 33$5Į (374-fold) > 33$5Ȗ(1.00). In HeLa cells, 33$5ȕ was again 
the most expressed isotype followed by much lower levels of PPARĮ and 
PPARȖ. The fold expression in this case was: PPARɴ (142-fold) > 33$5Į 
(2.8-fold) > 33$5Ȗ (1.00). 
 
tarȀȾ-actin 
(a.u.) 
SH-SY5Y  HeLa 
 
Positive ctrl 
 
Tissue 
PPARɲ 1.24E-03 
±3.24E-05 
1.17E-04 
±8.30E-06 
6.25E-03 
±1.73E-03 
Human 
Liver 
PPARɴ 3.85E-02 
±2.45E-03 
5.90E-03 
±3.99E-04 
2.57E-02 
±7.45E-03 
Human 
Liver 
PPARɶ 3.31E-06 
±9.93E-07 
4.16E-05 
±4.36E-06 
6.69E-04 
±1.94E-04 
Human 
Liver 
 
Table 3.2: qRT-PCR analysis of mRNA expression in SH-SY5Y cells. Results 
DUH H[SUHVVHG DV DYHUDJH DUELWUDU\ XQLWV QRUPDOLVHG E\ ȕ-actin, measured in 
triplicate. mRNA or total RNA was extracted from SH-SY5Y cells, HeLa cells 
as control cell line and either human liver, spleen or brain as a positive control.  
 
3.2.2.2. Protein expression 
Differential expression among the PPARs isotypes was confirmed by Western 
blotting of protein preparations from cells separated by SDS polyacrylamide 
gel electrophoresis (Figure 3.4). Expected sizes were: 52 kDa (33$5Į), 50 
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kDa (33$5ȕ), and 58 kDa (33$5Ȗ). All the antibodies used showed staining 
at slightly larger molecular sizes than expected. 33$5ȕ and 33$5Į proteins 
were detected in both cell lines while 33$5Ȗ staining was apparent only in 
HeLa cells. Levels of relative protein expression of the various PPARs 
isotypes were consistent with RNA levels reported in the previous section.  
 
   33$5Į                         33$5ȕ                                   33$5Ȗ   
 
 (1)       (2)          (3)         (1)           (2)        (3)        (1)           (2)          (3) 
Figure 3.4: Western blotting of either 30 µg SH-SHY5Y (lanes 1) or 30 µg 
HeLa (lanes 2) protein using antibodies against 33$5Į (Sigma), 33$5ȕ 
(SantaCruz) and 33$5Ȗ (Cell Signalling). The membrane was scanned with an 
Odyssey scanner (LI-COR Biosciences). Lanes 3 show SeeBlue Plus2 MW 
ladder (Invitrogen). 
 
148 kDa 
98 kDa 
64 kDa 
50 kDa 
36 kDa 
22 kDa 
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3.3. Discussion 
The presence of the machinery to synthesize and break down 
endocannabinoids was revealed in both neuroblastoma SH-SY5Y and HeLa 
cells together with the two cannabinoid receptors, at least at the mRNA level. 
These results are consistent with very recent findings showing expression of a 
fully functional endocannabinoid system in SH-SY5Y neuroblastoma cells 
(Marini et al., 2009; Pasquariello et al., 2009). FAAH expression was 
confirmed at the protein level in SH-SY5Y cells, but not in HeLa cells; the 
latter observation confirming a previous report (Day et al., 2001). Differential 
FAAH expression was also reflected in AEA hydrolysis activity that was 
absent in HeLa cells and present in neuroblastoma cells (Figure 3.2). However, 
the presence of mRNA encoding other enzymes involved in endocannabinoid 
hydrolysis (most notably FAAH-2 in HeLa cells), prompted us to monitor 
hydrolysis of ODA, the main substrate for this enzyme (Wei et al., 2006). 
Results showed that both cell lines could hydrolyse ODA and this activity was 
reversed by URB597, which inhibits both FAAH and FAAH-2 with similar 
potency (Wei et al., 2006). HeLa cells appeared to selectively catabolise ODA 
over AEA under the conditions used in this study.  
 
Expression of PPAR nuclear receptors measured at both mRNA and protein 
levels revealed that 33$5ȕ was the most abundant isotype in both cell lines, 
followed by 33$5Į This pattern of expression might reflect a role for 33$5ȕ 
in the regulation of tumour cell growth even if the literature reports conflicting 
data (Bishop-Bailey et al., 2009). Moreover, activation of 33$5ȕ receptors 
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has previously been linked with SH-SY5Y cell differentiation into neuronal-
like cells (Di Loreto et al., 2007). Data in the present study showed that 
33$5Ȗ was expressed in HeLa cells while RNA levels of this receptor in SH-
SY5Y cells were really low and protein was not detected by immunoblotting in 
these cells. These findings are partially inconsistent with previous studies 
showing 33$5Ȗ expression in SH-SY5Y cells (Valentiner et al., 2005). 
However, among the various neuroblastoma cell types tested, SH-SY5Y cells 
showed the lowest level of expression in both immunohistochemistry and 
western blot analysis with nuclear staining in these cells virtually negative. 
Moreover, the PPARȖ ligand rosiglitazone could inhibit cell adhesion, 
invasiveness and apoptosis in SK-N-AS, a PPARȖ positive neuroblastoma cell 
line, while it was ineffective in SH-SY5Y cells (Cellai et al., 2006) 
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4. EFFECTS OF FAAH 
INHIBITION ON FAAs LEVELS 
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4.1. Introduction 
In the previous section, SH-SY5Y cells were shown to express functional 
FAAH activity, while HeLa cells were shown to be FAAH negative. Given 
that FAEs appear to be hydrolysed to ethanolamine and fatty acids principally 
through the action of FAAH, inhibition of FAAH should lead to accumulation 
of a variety of intracellular FAEs. In this study, this possibility was tested in 
SH-SY5Y cells as a model of neuronal cells and HeLa cells as an FAAH 
negative control. 
 
4.1.1. FAAH expression and activity 
SH-SY5Y cells were treated with the FAAH inhibitor URB597 for 24 hours 
and changes in FAAH expression were monitored at both the RNA and the 
protein levels. For the qRT-PCR measurements, the geometric mean of two 
separate reference genes (ɴ-actin-B2M) was used to normalise RNA values. 
Time-course of inhibition of FAAH activity was monitored following 
liberation of tritiated ethanolamine from labelled AEA in either cell 
homogenates or intact cells. In addition to URB597, two structurally and 
functionally distinct FAAH inhibitors, OL135 and PF750, were tested 
(Lichtman et al., 2002) (Ahn et al., 2007). Changes in 2OG hydrolysis rate 
were also monitored in intact cells. 
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4.1.2. ECs measurement 
ECs measurements were performed by Dr. Leonie Norris in the School of 
Pharmacy (University of Nottingham). Intracellular ECL levels were 
monitored after 24 hours of URB597 treatment in both SH-SY5Y and HeLa 
cells by LC-MS/MS as previously described (Richardson et al., 2007). Data 
were normalised by cell number in order to account for morphological 
differences between cell types. 
 
4.1.3. RNA interference 
In order to show that the pharmacological treatments used in this study were 
selectively targeting FAAH, FAAH knock down by RNA interference in SH-
SY5Y cells was attempted. Various technologies were applied including 
miRNA, siRNA and shRNA (see Chapter 2).  
 
4.1.4. Cell viability 
In order to check whether the FAAH inhibitors were affecting cell viability at 
the concentrations used in the study, neutral red uptake by SH-SY5Y cells was 
monitored. This widely used assay is based on the ability of viable cells to 
incorporate the supravital dye neutral red, a weakly cationic dye. Neutral red 
penetrates cell membranes by non-ionic passive diffusion and concentrates in 
the lysosomes, where it binds by electrostatic hydrophobic bonds to anionic 
and/or phosphate groups of the lysosomal matrix. When the cell dies or the pH 
gradient is reduced, the dye cannot be retained. Consequently, the amount of 
retained dye is proportional to the number of viable cells (Repetto et al., 2008). 
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4.1.5. Calcium mobilization 
Recently, URB597 was proposed to activate TRPA1 and inhibit TRPM8 
receptors (Niforatos et al., 2007). These receptors are ligand-activated non-
selective cation channels able to gate calcium influx. In order to rule out the 
possibility of this mechanism being involved in this study, intracellular 
calcium mobilization was monitored in both SH-SY5Y and HeLa cells in 
response to URB597 administration.  
 
4.2. Results 
4.2.1. FAAH expression 
Expression of FAAH in SH-6<<FHOOVZDVPRQLWRUHGDIWHUKRXUVRIȝ0
URB597 treatment at the mRNA and protein levels. FAAH mRNA expression 
was 1.04 ± 0.15 after vehicle (DMSO 0.1%) treatment and remained at a value 
of 0.93 ± 0.11 after URB597 treatment (arbitrary units, normalised to 
expression of ɴ-actin-B2M, n=3). Western blotting of protein preparations 
from treated SH-SY5Y cells showed no difference in FAAH protein levels 
after either vehicle (DMSO 0.1%) or URB597 treatment (n=2, Figure 4.1) 
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Figure 4.1: Western blotting of 30 µg SH-SHY5Y protein using antibodies 
against FAAH (Millipore) or actin (Sigma). The membranes were scanned 
with an Odyssey scanner (LI-COR biosciences). The protein sizes indicated on 
the right result from MW markers of the SeeBlue Plus2 ladder (Invitrogen). 
 
4.2.1.1. AEA hydrolysis 
4.2.1.1.1. Cell homogenate 
Cells were treated with  ȝ0 URB597 either with continuous exposure for 
different times up to 24 hours or for 30 mins after which the medium was 
changed, following which AEA hydrolysis was measured in SH-SY5Y cell 
homogenates. Inhibition of FAAH activity (AEA hydrolysis) was achieved 
inside 30 minutes and sustained over time following either 30 minutes or 
continuous URB597 treatment (P<0.001, Figure 4.2). 
85%0ʊ9HKLFOH'062
Anti FAAH Ab (Chemicon)
Anti actin Ab (Sigma)
ʊ 64 kDa
ʊ 50 kDa
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Figure 4.2: Time course of URB597-evoked inhibition of AEA hydrolysis in 
SH-SY5Y cell homogenates. Results are expressed as a percentage of control 
at t=0 (***P<0.001 compared to control, n=3). 
 
4.2.1.1.2. Intact cells 
4.2.1.1.2.1. Time course 
Cells were treated with 1 µM URB597 as above, either continuously for 
different times up to 24 hours or for 30 mins after which the medium was 
changed, measuring AEA hydrolysis in intact SH-SY5Y cells. Inhibition of 
FAAH activity (AEA hydrolysis) was achieved inside 30 minutes and 
sustained over time by either 30 minutes or continuous URB597 treatment 
(P<0.001 and P<0.01 respectively, Figure 4.3). A residual activity of around 
25% of control was detected. 
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Figure 4.3: Time course measurement of AEA hydrolysis in intact SH-SY5Y 
cells. Results are expressed as percentage of control at t=0 (**P<0.01 and 
***P<0.001 compared to control, n=3).  
 
4.2.1.1.2.2. Concentration-response] 
Cells were treated for 24 hours with increasing concentrations of three 
different FAAH inhibitors (OL135, URB597 and PF750). All the FAAH 
inhibitors tested were able to inhibit AEA hydrolysis in a concentration-
dependent fashion. IC50 (95% C.I.) values were 4.2x10-6 M (2.3x10-6 to 
7.5x10-6) for OL135, 3.4x10-9 M (2.1x10-9 to 5.4x10-9) for URB597 and 
3.2x10-10 M (1.9x10-10 to 5.6x10-10) for PF750. A residual activity of around 
25% of control was detected that only the highest concentration of URB597 (-
4.5 log M) could inhibit (Figure 4.4). 
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Figure 4.4: Concentration-response effects of FAAH inhibitors on AEA 
hydrolysis in intact SH-SY5Y cells. Results are expressed as percentage of 
control (n=3). 
 
4.2.1.1.2.3. Extended and brief FAAH inhibition 
Measurement of AEA hydrolysis in intact SH-SY5Y cells showed that 
extended (24 hours) treatment with  ȝ0 URB597 could not completely 
inhibit AEA hydrolysis (P<0.001, Figure 4.5 a and b). Acute (30 minutes) pre-
incubation of cells with either 10 or 30 µM URB597 following 24 hour 
treatment with  ȝ0 URB597 could almost completely inhibit the residual 
activity down to levels achieved by 24 hour treatment with 30 µM URB597 
(P<0.05, a). Moreover, acute pre-incubation of cells with 60 µM of the NAAA 
inhibitor CCP following 24 hour treatment with ȝ0URB597 could almost 
completely inhibit the residual activity down to levels achieved by 24 hour 
treatmenWZLWKȝ085%3b).  
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  (a) 
 
  (b) 
 
Figure 4.5: Measurement of AEA hydrolysis in intact SH-SY5Y cells 
following extended (24 hours) and brief (30 mins pre-incubation, in brackets) 
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treatment with either URB597 (a) or CCP (b). Results are expressed as 
percentage of control (n=3, *** P<0.001 compared to control, # P<0.05 
compared to 10 µM URB597). Typical basal AEA hydrolysis was 1.2 ± 0.1 
pmol/min/well (mean ± SD). 
 
4.2.1.2. 2OG hydrolysis 
Measurement of 2OG hydrolysis in intact SH-SY5Y cells following extended 
(24 hours) or brief (30 mins pre-incubation) treatment, showed that  ȝ0
MAFP could inhibit 2OG hydrolysis in SH-SY5Y cells both acutely (P<0.001) 
or after 24 hour treatment (P<0.05, Figure 4.6). By contrast, ȝ0URB597 
was unable to inhibit 2OG hydrolysis. Basal 2OG hydrolysis was 1.37 ± 0.38 
pmol/min/well (mean ± SD). 
 
 
Figure 4.6: Measurement of 2OG hydrolysis in intact SH-SY5Y cells 
following extended (24 hours) or brief (30 min pre-incubation, in brackets) 
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treatment with either ȝ0MAFP or ȝ0URB597. Results are expressed 
as percentage of control (Q * P<0.05, *** P<0.001 compared to control). 
 
4.2.2. ECL measurements 
Cells were treated with either DMSO or 10 µM URB597 for 24 hours. Cells 
were then harvested and lipids were extracted, together with internal standards. 
LC-MS/MS measurements of AEA, OEA, PEA and 2AG levels in SH-SY5Y 
cells showed that AEA, PEA and 2AG levels were significantly increased after 
 ȝ0 URB597 treatment (P<0.01, P<0.05 and P<0.01 respectively), while 
OEA levels were unaffected. In HeLa cells, PEA levels were significantly 
LQFUHDVHG DIWHU  KRXUV RI  ȝ0 8RB597 treatment (P<0.05, Table 4.1) 
while AEA, OEA and 2AG levels were unaffected. 
 
 SH-SY5Y HeLa 
 Vehicle (DMSO) 
fmol/106cells 
median (range) 
URB597 10µM 
fmol/106cells 
median (range) 
Vehicle (DMSO) 
fmol/106cells 
median (range) 
URB597 10µM 
fmol/106cells 
median (range) 
AEA 338 
(282 / 431) 
648** 
(467 / 729) 
503 
(194 / 598) 
436 
(385 / 502) 
OEA 4850 
(2940 / 6590) 
5810 
(4590/ 10300) 
4250 
(2350 / 5870) 
4030 
(3220 / 7110) 
PEA 11100 
(7430 / 16800) 
17000* 
(14400 / 19900) 
9100 
(5240 / 13400) 
15500* 
(12200 / 23000) 
2AG 6590 
(5490 / 8050) 
13800** 
(11100 / 16100) 
2070 
(1470 / 4870) 
2000 
(1520 / 4180) 
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Table 4.1: LC-MS/MS measurements of AEA, OEA, PEA and 2AG levels in 
SH-SY5Y and HeLa cells. Results are expressed as fmol/106 cells, median 
values (range). (measured by Dr Leonie Norris. *P<0.05, **P<0.01 and 
**P<0.01, n=5) 
 
4.2.3. RNA interference 
SH-SY5Y cells were treated with siRNAs, miRNAs or shRNAs and FAAH 
expression was determined at the mRNA level. siRNAs delivered by 
Nucleofection (see Chapter 2) successfully knocked down actin as a positive 
control (25.9 ± 5.9 % of control) while they could only knock down FAAH 
levels to 61.6 ± 21.7% of control. siRNAs delivered with Dharmacon reagent 
successfully knocked down the positive control GAPDH (13.7 ± 0.8% of 
control) while the best construct tested (14) could knock down FAAH levels to 
49.1 ± 9.7 % of control. miRNA-expressing plasmids were unsuccessful in 
knocking down FAAH (no positive control used). Finally, shRNAs delivered 
as viral particles knocked down the positive control B2M to 64.1 ± 5.0 % of 
control while the best construct against FAAH (36FAAH) could only knock its 
RNA levels down to 70.2 ± 10.9 % of control when transduced at MOI=3 
(Table 4.2). 
 
Technology 
 
Construct ID 
 
FAAH % of control 
Mean±SD 
Positive % control 
Mean±SD (gene) 
siRNA 
Ambion+Nucleofector 
1+3 
61.6±21.7 
n=7 
25.9±5.9 (Actin) 
n=2 
siRNA 14 49.1±9.7 13.7±0.8 (GAPDH) 
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Dharmacon n=6 n=6 
 
15 
68.3±11.5 
n=6 
 
 
16 
53.5±2.5 
n=6 
 
 
17 
63.6±5.7 
n=6 
 
 
SmartPool 
(14+15+16+17) 
75.7±8.7 
n=6 
 
miRNA 
Invitrogen 
293 (1) 106.4 
n=1 
N.D. 
 
293 (2) 152.6 
n=1 
 
 590 (1) 
93.2 
n=1 
 
 
590 (2) 93.2 
n=1 
 
shRNA 
Sigma 
34FAAH MOI=1 
77.7±6.2 
n=3 
64.1±5.0 (B2M) 
n=3 
 34FAAH MOI=3 
73.9±7.6 
n=3 
 
 
35FAAH MOI=1 
72.7±6.4 
n=3 
 
 
35FAAH MOI=3 
74.7±3.7 
n=3 
 
 
36FAAH MOI=1 
73.2±7.8 
n=3 
 
 
36FAAH MOI=3 
70.2±10.9 
n=3 
 
 
37FAAH MOI=1 
74.5±6.6 
n=3 
 
 
37FAAH MOI=3 
82.4±4.0 
n=3 
 
 38FAAH MOI=1 
95.0±7.8 
n=3 
 
 
38FAAH MOI=3 
84.3±2.9 
n=3 
 
 
Table 4.2: Expression of either FAAH or a control gene after various RNAi 
treatments in SH-SY5Y cells. 
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4.2.4. Cell viability 
Neutral Red uptake was measured in SH-SY5Y cells after treatment with either 
DMSO, increasing concentrations of URB597, OL135, PF750 or 0.1 % 
saponin as a positive control. Results showed that none of the FAAH inhibitors 
affected cell viability at all concentrations tested (Figure 4.7). 
 
Figure 4.7: Neutral Red uptake was measured in SH-SY5Y cells after 24 
hours treatment with the FAAH inhibitors. Results are expressed as percentage 
of control (n=3) 
 
4.2.5. Calcium mobilization 
Intracellular Ca2+ measurements showed that, although carbachol evoked 
significant elevations in [Ca2+]i in both SH-SY5Y and HeLa cells (P<0.001) 
compared to vehicle control (not shown, 0%),  ȝ0 URB597 and the 
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TRPM8 ligand menthol (100 nM) were without effect. 1 mM ATP 
significantly elevated [Ca2+]i in HeLa cells (P<0.001, Figure 4.8 a and b) while 
it could only slightly elevate [Ca2+]i in SH-SY5Y cells. 
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Figure 4.8: Intracellular Ca2+ mobilization in SH-SY5Y (a) and HeLa cells 
(b). Results are expressed as a percentage of carbachol response (*** P<0.001 
compared to control, not shown, n=6). 
 
4.3. Discussion 
In this section, inhibition of FAAH activity in SH-SY5Y cells was achieved by 
1 µM URB597 treatment for either 30 minutes or 24 hours continuous 
treatment as shown by AEA hydrolysis inhibition in cell homogenates (Figure 
4.2). In order to verify this inhibition in a more physiologically relevant way, 
AEA hydrolysis was measured in intact SH-SY5Y cells. The same URB597 
treatment elicited FAAH inhibition that was achieved inside 30 minutes and 
sustained over time. However, a residual FAAH activity of around 25% was 
still detected (Figure 4.3). It has been previously shown that sustained and 
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nearly complete FAAH inhibition is required to maintain elevated ECs levels 
in vivo (Fegley et al., 2005). Concentration-response experiments treating SH-
SY5Y cells with URB597, OL135 and PF750 showed that these compounds 
could all inhibit FAAH activity in neuroblastoma cells to similar levels 
although with different potencies. PF750 appeared to be the most potent 
FAAH inhibitor, with OL135 the least potent. However, a residual AEA 
hydrolysis activity was measurable after treatment with all three inhibitors 
(Figure 4.4). Acute re-H[SRVXUHWRȝ085%RUH[WHQGHGWUHDWPHQWZLWK
a higher concentration of URB597 (30 µM) could further inhibit the residual 
AEA hydrolysis (Fig 4.5a) pointing towards the possibility of newly 
synthesised FAAH being responsible for this activity. A potential alternative is 
that URB597 is being hydrolysed or accumulated in other compartments where 
it cannot inhibit FAAH, which might explain the need for either higher chronic 
concentrations or freshly administered URB97. However, acute treatment with 
the NAAA inhibitor CCP 30-60 µM could also knock down the residual AEA 
hydrolysis activity (Figure 4.5b). CCP has been shown to selectively inhibit 
NAAA without inhibiting FAAH up to concentration of at least 100 µM 
(Tsuboi et al., 2004), with which local studies concur (Patel & Alexander, 
personal communication). More recently, a more selective NAAA inhibitor, 
(S)-OOPP, has been reported to augment PEA levels in activated leukocytes 
(Solorzano et al., 2009). On the contrary, URB597 has very recently been 
shown to weakly inhibit (around 25%) recombinant rat NAAA at 100 µM 
(Solorzano et al., 2009). Moreover, expression of NAAA has been confirmed 
in SH-SY5Y cells at least at the mRNA level (see Chapter 2). Taken together, 
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these data would indicate that the residual AEA hydrolysis activity after 
URB597 treatment in SH-SY5Y cells might be due to NAAA activity.  
 
Increased levels of intracellular AEA, PEA and 2AG but not OEA were 
measured in SH-SY5Y cells after 24 hours oIȝ085%H[SRsure (Table 
4.1). URB597 is reported not to inhibit MGL, the main enzyme hydrolysing 
2AG, up to concentrations of at least 30 µM (Kathuria et al., 2003). However, 
2AG has been previously showed to be hydrolysed by FAAH under particular 
circumstances (Di Marzo et al., 2008). This appeared not to be the case in SH-
6<<FHOOV,QGHHGȝ085%GLGQRWDOWHUK\GURO\VLVRI2*DFORVH
analogue of 2AG widely used in radioactivity-based MGL assays. On the 
FRQWUDU\  ȝ0 0$)3 DQ LQKLELWRU RI ERWK )$$+ DQG 0*/ FRXOG
significantly diminish 2OG hydrolysis (Figure 4.6). Expression of MGL has 
been confirmed at the mRNA level in both SH-SY5Y and HeLa cells (see 
Chapter 3). However, the possibility of 2AG being hydrolysed by FAAH 
selectively over 2OG has not been addressed.  
 
Surprisingly, PEA levels were elevated in HeLa cells after URB597 treatment 
(Table 4.1). PEA is hydrolysed primarily by FAAH and NAAA, and it is 
thought to be the main substrate for the latter enzyme (Ueda et al., 2001). 
Another enzyme, FAAH-2, can also break down PEA (Wei et al., 2006) and 
inhibition of either its activity or NAAA activity by URB597 might well be 
responsible for intracellular PEA levels elevation. In Chapter 3, HeLa cells 
were indeed shown to express both FAAH-2 and NAAA RNA. Moreover, 
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HeLa cells were able to hydrolyse exogenous ODA, the main substrate for 
FAAH-2. This activity was reversed by URB597 pre-incubation.  
 
A recent publication showed that URB597 can activate TRPA1 receptors and 
inhibit TRPM8 receptors (Niforatos et al., 2007). Intracellular calcium ion 
measurements reported in the present study ruled out the involvement of 
TRPA1 receptor in the mechanism by which URB597 elevated ECL levels in 
SH-SY5Y or HeLa cells. Indeedȝ085%DFRQFHQWUDWLRQWLPHV
higher than the one used for ECL levels measurement) had no effect on 
calcium mobilization in both SH-SY5Y and HeLa cells. Menthol, a TRPM8 
ligand, did not affect intracellular calcium levels either, indicating that this 
receptor is either not expressed or not functional in either SH-SY5Y nor HeLa 
cells (Figure 4.8 a and b respectively). Moreover, a recent publication (Vetter 
et al., 2009) reported that capsaicin could not affect calcium measurements in 
SH-SY5Y cells, possibly suggesting that TRPV1 receptors are also not present 
in this cell line. There is strong debate in literature about the notion of ECLs 
being synthesised on demand after an external stimulus. The activity of the 
anabolic enzyme NAPE-PLD was indeed shown to be activated by high 
concentrations of Ca2+ (Wang et al., 2006). Another study  recently reported 
intracellular elevation of ECs in mixed cultures of neurones and astrocytes 
after AMPA or NMDA treatment (Loría et al., 2009). AEA, 2AG and PEA 
were elevated in quantities comparable to the ones shown in the present study. 
The elevation of AEA, PEA and 2AG in SH-SY5Y cells and of PEA in HeLa 
cells reported here after inhibition of either FAAH or FAAH-2 and possibly 
NAAA, indicates that it is possible to modulate ECL levels in cultured cells by 
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simply modulating their metabolism. This would point in favour of an 
underlying ECL tone, regardless of external stimulation. Notably, all the 
FAAH inhibitors were shown not to affect SH-SY5Y cell viability at any 
concentration tested (Figure 4.7). 
 
RNA interference targeting FAAH in SH-SY5Y cells was able to produce a 
knockdown of the FAAH gene but at levels that were not considered good 
enough for our purposes. miRNA expressing plasmid transfection or shRNA 
plasmid viral transduction could only slightly diminish FAAH mRNA levels. 
siRNA transfection, exploiting either nucleofection or Dharmacon passive 
delivery, appeared to be the most reliable technique to knock down this 
enzyme in SH-SY5Y neuroblastoma cells. However, FAAH mRNA levels 
were only knocked down to 49.1 ± 9.7% of control (Table 4.2) with the best 
construct out of four. As already mentioned, it would appear that a complete 
inhibition of FAAH is required in order to maintain elevated ECL levels 
(Kathuria et al., 2003). Thus, only pharmacological inhibition of this enzyme 
was conducted for the next experiments of this study.  
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5. EFFECT OF THE FAAH 
INHIBITORS ON PPARs 
ACTIVATION 
  
Endocannabinoid metabolism and PPARs signalling 
 
Effects of the FAAH inhibitors on PPARs activation - 84 
 
5.1. Introduction 
In the previous chapter, URB597 and two other structurally and functionally 
distinct FAAH inhibitors, OL135 and PF750, were shown to inhibit FAAH 
activity in SH-SY5Y cells. It waV WKHQ GHPRQVWUDWHG KRZ  ȝ0 85%
augmented AEA, PEA and 2AG levels in this cell line. In HeLa cells, URB597 
inhibited ODA hydrolysis and augmented only PEA levels in this cell line. In 
this section, the possibility of transactivating PPAR nuclear receptors 
following pharmacological inhibition of FAAH in both SH-SY5Y and HeLa 
cells was addressed.  
 
5.1.1. Reporter gene assay  
In the literature, two distinct reporter gene assays are usually conducted in 
order to measure PPAR activation. The first one exploits expression of PPARs 
as GAL4-DBD (DNA binding domain) fusion protein, which binds to the UAS 
promoter containing generally four copies of a synthetic GAL4 binding site 
upstream to the minimal thymidine kinase (TK) promoter. The GAL4-
DBD/PPAR fusion protein activates the reporter gene in response to agonist 
binding (Liu et al., 2003). However, this method does not take into 
consideration any interaction with co-activators or co-repressors. 
Transactivation of PPARs measured in this way might not actually reflect a 
real activation in a more physiologically relevant situation that can be created 
with the presence of co-regulators. For this reason, a firefly luciferase reporter 
gene assay was used in this study. The plasmid construct was transiently 
transfected in the cells and was under the control of three copies of PPRE 
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(peroxisome proliferator responsive element) upstream to the minimal TK 
promoter. Ligand binding induced transcription of the reporter gene. A major 
drawback of this method is the possibility of endogenous PPARs contributing 
to the measured reporter gene activation . For this reason and in order to test 
selectivity of activation, pharmacological studies employing selective PPAR 
antagonists were carried out. Some authors use a dual luciferase assay to 
normalise their data. This method is based on co-transfection of a plasmid 
expressing renilla luciferase in order to monitor the quality of transfection. 
Other authors co-transfect a ɴ-galactosidase expressing plasmid instead. The 
substrate is then added and detection of the yellow product allows 
normalisation of  data to a value directly correlated with the quality of 
transfection. However, previous data from the labs in Nottingham indicated 
that these co-transfection protocols might interact and interfere with the 
experimental setup giving unstable reporter gene readings. For this reason, data 
in this study were normalised to protein levels. This also allowed us to exclude 
data sets that differed from the control protein levels, an indication of possible 
toxicity of the tested compound. 
 
5.1.2. PPAR binding assays 
The PPAR binding assays used in this section are based on displacement of 
either cis-parinaric acid 33$5Į RU Fluormone a pan-PPAR fluorescent 
DJRQLVW33$5ȕDQG33$5Ȗ, from the PPAR ligand binding domain. Assays 
based on Fluormone displacement are commercially available (Invitrogen) 
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and exploit either TR-FRET technology (33$5ȕ) or fluorescence polarization 
(33$5Ȗ) 
 
5.2. Results 
5.2.1. Transactivation of endogenous PPARs 
Cells were treated with either DMSO, ȝ0URB597 or two applications of 
of ȝ0OL135 for 24 hours. ȝ0:<ȝ0*:DQGȝ0
URVLJOLWD]RQHZHUHXVHGDVSRVLWLYHFRQWUROV IRU33$5Į 33$5ȕDQG33$5Ȗ
respectively. In SH-SY5Y cells, both URB597 and OL135 caused significant 
activation of endogenous PPARs (P<0.01 and P<0.001 respectively). Both the 
PPARȕ ligand GW0742 and the PPARȖ ligand rosiglitazone elevated 
endogenous PPAR activation (P<0.001 and P<0.01, respectively), while the 
PPARĮ ligand WY14643 had only a small effect. In HeLa cells, neither of the 
FAAH inhibitors tested had any effect on endogenous PPAR activation. 
However, both the PPARȕ ligand GW0742 and the PPARȖ ligand 
rosiglitazone stimulated endogenous PPAR activation (P<0.001, Figure 5.1) 
while the PPARĮ ligand WY14643 had no effect. 
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Fig 5.1: Reporter gene activation in SH-SY5Y and HeLa cells transfected with 
a 3xPPRE-TK Luciferase construct. OL135 was applied two times over 24 
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hours. Results are expressed as fold activation from control (**P<0.01 and 
3FRPSDUHGWRYHKLFOHQ).  
 
5.2.2. Transactivation of over-expressed PPARs 
5.2.2.1. SH-SY5Y cells 
Cells were treated with '062ȝ02/RUincreasing concentrations of 
URB597 for 24 hours. URB597 appeared to be able to induce activation of 
33$5ȕ DQG 33$5Ȗ LQ D FRQFHQWUDWLRQ GHSHQGHQW IDVKLRQ ZKLOH LW KDG D
ELSKDVLFHIIHFWRQ33$5ĮDFWLYDWLRQ85%DSSHDUHGWRbe more potent in 
activating 33$5ȕ out of the three different isotypes. Indeed, the threshold 
URB597 concentration to activate 33$5ȕZDV µM (P<0.001, Figure 5.2). 
Another FAAH inhibitor, OL135 at 10 µM, could transactivate all three PPAR 
isotypes. When expressed as a proportion of the response to the isotype-
selective ligand, both URB597 and OL135 appeared to be most efficacious in 
DFWLYDWLQJ33$5ȕ, compared to the other two isotypes. 
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Fig 5.2: Reporter gene activation in SH-SY5Y cells transfected with a 
3xPPRE-TK Luciferase construct in combination with a PPARĮ, 33$5ȕ or 
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PPARȖ2 expressing plasmid. OL135 was applied two times over 24 hours. 
Results are expressed as fold activation relative to control (*P<0.05, **P<0.01 
and ***P<0.001 compared to control, n=6, representative of two separate 
experiments). 
 
5.2.2.2. HeLa cells 
Cells were treated with '062ȝ02/RUincreasing concentrations of 
URB597 for 24 hours. URB597 did not show a clear concentration dependency 
in PPAR activation. Indeed, URB597 appeared to be either ineffective at low 
concentrations or to diminish basal activation at high concentrations in both 
PPARɲ- and PPARɴ-overexpressing HeLa cells. In PPARɶ-expressing cells, 
URB597 had a bell-shaped effect, augmenting basal activation at mid-
micromolar concentrations. The most efficacious concentration was 10 µM 
3 6LPLODUO\  ȝ0 2/ activated PPARɶ (P<0.001), although it 
was ineffective in PPARɲ- and PPARɴ-overexpressing cells. 
Endocannabinoid metabolism and PPARs signalling 
 
Effects of the FAAH inhibitors on PPARs activation - 91 
 
 
Fig 5.3: Reporter gene activation in HeLa cells transfected with a 3xPPRE-TK 
Luciferase construct in combination with a PPARĮ, 33$5ȕ or PPARȖ2 
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expressing plasmid. OL135 was applied two times over 24 hours. Results are 
expressed as fold relative to control (*P<0.05, **P<0.01 and ***P<0.001 
compared to control, n=6, representative of two separate experiments) 
 
5.2.3. Selectivity of PPAR activation in SH-SY5Y cells 
The selectivity of exogenous 33$5Į33$5ȕand 33$5Ȗ activation E\ȝ0
URB597 in SH-SY5Y cells was confirmed by treating cells with selective 
DQWDJRQLVWV 7KH 33$5Į DQWDJRQLVW *:  µM) was able to reverse 
P3$5Į activaWLRQE\ERWKȝ085%DQGȝ0:<3
+RZHYHU  ȝ0 *: ZDV DOVR DEOH WR LQKLELW EDVDO UHSRUWHU JHQH
DFWLYDWLRQ RQ LWV RZQ 3 7KH 33$5ȕ DQWDJRQLVW GSK0660 (1 µM), 
could inhibit basal 33$5ȕ activation on its own and completely reverse 
activation by ȝ0URB597 (P<0.05 and P<0.001 respectively). ,Q33$5Ȗ-
RYHUH[SUHVVLQJFHOOVWKH33$5ȖDQWDJRQLVW*:LQKLELWHGWUDQVDFWLYDWLRQ
E\  ȝ0 URVLJOLWD]RQH 3 +RZHYHU WKH VHOHFWLYH 33$5Ȗ DQWDJRQLVW 
was not able to reverse transDFWLYDWLRQE\ȝ085% 
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Fig 5.5: Reporter gene activation in SH-SY5Y cells transfected with a 
3xPPRE-TK Luciferase construct in combination with a 33$5Į 33$5ȕ RU
33$5Ȗ expressing plasmid. Results are expressed as fold relative to control. 
(*P<0.05, **P<0.01 and ***P<0.001 compared to control, ###P<0.001 
compared to  ȝ0 URB597 ,    3 FRPSDUHG WR  ȝ0 :<
3FRPSDUHGWRȝ0URVLJOLWD]RQH n6) 
 
5.2.4. PPAR activation by PF750 in SH-SY5Y cells 
Cells were treated with either DMSO or three separate FAAH inhibitors for 24 
hours.  ȝ0 URB597,  ȝ0 PF750 or WZR GRVHV RI  ȝ0 2/
significantly activated either endogenous PPAR activation (a, P<0.01, P<0.001 
and P<0.001 respectively RU DFWLYDWLRQ RI KHWHURORJRXVO\ H[SUHVVHG 33$5ȕ
(b, ***P<0.001, *P<0.05 and ***P<0.001 respectively). 
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(a) 
 
(b) 
 
Fig 5.4: Reporter gene activation in SH-SY5Y cells transfected with a 
3xPPRE-TK Luciferase construct either alone (a) or in combination with a 
33$5ȕH[SUHVVLQJSODVPLGb). OL135 was applied two times over 24 hours. 
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Results are expressed as fold relative to control. (*P<0.05, **P<0.01 and 
***P<0.001 compared to vehicleQ 6). 
 
5.2.5. PPAR binding assays 
5.2.5.1. FAAH inhibitors 
Binding of FAAH inhibitors to PPARɲ͕ PPARɴ and PPARɶ ligand binding 
domains was tested using as positive controls WY14643, GW0742 and 
rosiglitazone, respectively. IC50 (95% C.I.) values: WY14643 3.1x10-6 M 
(1.6x10-6 to 6.2x10-6) GW0742 3.3x10-10 M (1.7x10-10 to 6.6x10-10) and 
rosiglitazone 3.5x10-8 M (3.1x10-8 to 4.0x10-8). Increasing concentrations of 
URB597, OL135 or PF750 failed to displace the competing ligand from the 
33$5ȕ ligand binding domain. Moreover, URB597 was not able to bind to 
HLWKHUWKH33$5ĮRUWKH33$5ȖOLJDQGELQGLQJGRPDLQ 
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Fig 5.6: TR-)5(7 33$5Į DQG 33$5ȕ RU )OXRUHVFHQFH 3RODULVDWLRQ
33$5Ȗ EDVHG FRmpetition displacement assays (Invitrogen) for the PPAR 
ligand binding domains (33$5Į n=3; 33$5ȕ/Ȗ n=2) 
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5.2.5.2. ECs and fatty acids 
Binding of a variety of ECLs (a) and fatty acids (b) to the PPARɴ ligand 
binding domain was tested using GW0742 as a positive control (IC50 value = 
6.7x10-10 M in a and IC50 value = 4.2x10-10 M in b). OEA and PEA failed to 
ELQG WR WKH 33$5ȕ ligand binding domain, while AEA and 2AG were both 
ligands (IC50 values = 1.4x10-5 and 8.3x10-5 M, respectively). Arachidonic acid 
(AA), palmitic acid (PA) and oleic acid (OA) could all displace the fluorescent 
ligand from the 33$5ȕ ligand binding domain. IC50 (95% C.I.) values: AA 
1.8x10-6 M (1.1x10-6 to 3.0x10-6); PA 1.7x10-6 M (9.0x10-7 to 3.4x10-6); OA 
6.8x10-7 M (3.8x10-7 to 1.2x10-6). 
 
(a) 
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(b) 
 
Fig 5.7: TR-FRET based displacePHQW DVVD\ IRU WKH 33$5ȕ OLJDQG ELQGLQJ
domain by ECLs (a) and fatty acids (b, n=2) 
 
5.3. Discussion 
5HSRUWHUJHQHDVVD\VRI WUDQVLHQWO\WUDQVIHFWHGFHOOVVKRZHGWKDWERWKȝ0
85% DQG  ȝ0 2/ FRXOG LQGXFH WUDQVDFWLYDWLRQ RI 33$5V
endogenously expressed in SH-SY5Y cells. In contrast, both FAAH inhibitors 
were ineffective in HeLa cells (Figure 5.1). The earlier characterization of SH-
SY5Y cells in Chapter 3 indicated that 33$5ȕZDVE\ IDU WKHPRVWDEXQGDQW
33$5 LVRW\SHH[SUHVVHG LQWKHVHFHOOV33$5ĮZDVexpressed at lower levels 
ZKLOH33$5ȖOHYHOV ZHUHDOPRVWXQGHWHFWHG6XUSULVLQJO\ȝ0URVLJOLWD]RQH
induced elevation of basal PPAR activation in SH-SY5Y cells. However, 
33$5Ȗ ligands such as rosiglitazone and other thiazolidinediones (TZDs) are 
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reported to activate MAPKs and activation of this pathway is believed to 
induce activation of PPARs by phosphorylation (Gardner et al., 2005). The 
33$5Į OLJDQG :<  ȝ0 FRXOG RQO\ VOLJKWO\ LQFUHDVH EDVDO 33$5
activity in SH-SY5Y. However, this could be explained by a constitutively 
high PPARĮ activation by endogenous ligands as well as by components of the 
serum (FBS concentration could only be lowered down to 0.5% in order to 
keep the cells viable).  
 
Pharmacological inhibition of FAAH by URB597 and OL135 was also 
GHPRQVWUDWHGWROHDGWRWUDQVDFWLYDWLRQRIRYHUH[SUHVVHG33$5Į33$5ȕDQG
33$5ȖLQ6+-SY5Y cells. However, low concentrations of URB597 appeared 
to significantly inhibit 33$5ĮDQG33$5ȕ basal activation. This effect might 
once again be explained by high basal activation of these receptors in SH-
SY5Y cells. Initial low potency inhibition of ECL hydrolysis by FAAH might 
lead to depletion of the pool of arachidonic acid and other FAs in the cells. A 
variety of saturated and unsaturated fatty acids are recognised endogenous 
ligands at PPARs, which may actually be involved in basal activation of these 
receptors. Among the FAs that are produced by hydrolysis of ECs and related 
molecules, arachidonic acid can transactivate all PPAR isotypes, while oleic 
and palmitic acids are ERWK33$5ĮDQG33$5Ȗ ligands (Figure 5.7b) (Berger 
et al., 2002). Subsequently, a greater inhibition of FAAH by slightly higher 
concentrations of URB597 might lead to higher accumulation of intracellular 
ECLs that would in turn activate PPARs. The possibility of URB597 directly 
binding to PPARs to induce their activation was also addressed in this study. 
Concentrations of up to 100 µM URB597 were only slightly able to displace 
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the fluorescent ligand IURP WKH 33$5ȕ DQG 33$5Ȗ OLJDQG ELQGLQJ GRPDLQ 
(Figure 5.6). This weak effect is highly unlike to be of any pharmacological 
relevance. 
 
To provide a further link between URB597- and OL135-induced PPAR 
transactivation and inhibition of FAAH, PF750 was shown to induce activation 
of both endogenous PPARs and over-expressed PPARȕ (Figure 5.4). While 
both URB597 and OL135 have been shown to have carboxylesterases as off-
targets, PF750 has been demonstrated to be very selective and not to interact 
with such targets (Ahn et al., 2007; Zhang et al., 2007)ȝ085%DQG
 ȝ0 3) DSSHDUHG WR KDYH VLPLODU HIILFDFLHV LQ DFWLYDWLQJ ERWK
endogenous PPARs and over-expressed PPARȕZKLOHȝ02/DSSHDUHG
to be slightly more efficacious (Figures 5.1, 5.2, 5.4). However, given that 
OL135 is the only reversible FAAH inhibitor examined in this study, two 
applications of this compound were used in these experiments in order to be 
sure of inducing an inhibition sustained over 24 hours. Cumulative or 
prolonged effects in elevation of intracellular ECLs by two applications of 10 
ȝ0 2/ PLJKW H[SODLQ D VWURQJHU HIIHFW LQ 33$5 DFWLYDWLRQ E\ WKLV
compound. URB597, OL135 and PF750 were demonstrated not to be ligands 
DWWKH33$5ȕOLJand binding domain (Figure 5.6) 
 
As already mentioned, reporter gene assays based on plasmids under the 
control of PPREs might lack selectivity if PPARs are endogenously expressed 
in the cells at high levels. The VHOHFWLYH33$5Įantagonist GW6471 (Xu et al., 
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2002) and GSK0660, a selective 33$5ȕDQWDJRQLVW (Shearer et al., 2008), were 
identified to completely reverse reporter gene activation by URB597 in SH-
SY5Y FHOOV RYHUH[SUHVVLQJ 33$5Į DQG 33$5ȕ UHVSHFWLYHO\ (Figure 5.3). In 
contrast, although the selective 33$5ȖDQWDJRQLVW*: (Leesnitzer et al., 
2002) was able to almost completely reverse reporter gene activation by 
rosiglitazone, it was ineffective in inhibiting transactivation of over-expressed 
33$5Ȗ (Figure 5.3). This lack of selectivity of the reporter gene assay based 
on co-transfection of PPARȖ might reflect the low endogenous expression of 
this receptor isotype compared to 33$5ĮDQG33$5ȕ in SH-SY5Y cells (see 
Chapter 3). While over-expressing one of these two receptors might be enough 
to confer selectivity over the other isotypes, overexpressing PPARȖ might not.  
 
In the previous chapter, levels of AEA, PEA and 2AG were demonstrated to be 
augmented in SH-S5Y after FAAH inhibition by URB597. Here, inhibition of 
FAAH was showed to transactivate all PPARs isotypes, or at least selectively 
activate ERWK 33$5Į DQG 33$5ȕ $($ KDV EHHQ SUHYLRXVO\ UHSRUWHG WR
transactivate and bLQGWRERWK33$5ĮDQG33$5Ȗ(Bouaboula et al., 2005; Sun 
et al., 2006). Moreover, 2AG was also demonstrated to transactivate both 
33$5Į DQG 33$5Ȗ (Kozak et al., 2002; Rockwell et al., 2006a). For 
completeness, in this study both AEA and 2AG were shown to be 33$5ȕ 
ligands while both PEA and OEA were not able to displace the fluorescent 
competitor (Figure 5.7a). This is in contrast with the reported activation of a 
GAL4-DBD/PPARȕ fusion protein by OEA previously reported by (Fu et al., 
2003). Reporter gene activity was measured after 7 hours following 
administration of exogenous OEA. Thus, activation of PPARȕ in this 
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timeframe might be due to OEA metabolites. However in the same study, the 
authors reported that OEA was able to both bind to and transactivate 33$5Į. 
Finally, PEA is also reported to transactivate 33$5Į (LoVerme et al., 2006); 
however, binding to the 33$5Į ligand binding domain is still to be 
demonstrated.  
 
In FAAH-negative HeLa cells, URB597 and OL135 were unable to 
transactivate overexpressed 33$5Į or 33$5ȕ. Surprisingly though, both 
URB597 and OL135 induced activation of over-expressed 33$5Ȗ in these 
cells (Figure 5.3). URB597 was shown to inhibit exogenous ODA hydrolysis 
in HeLa cells and these cells appeared indeed to express FAAH-2 (see Chapter 
3). Differential patterns in intracellular accumulation of ECLs after enzyme 
inhibition in SH-SY5Y and HeLa cells (see Chapter 4) might indeed explain a 
differential activation among the three PPAR isotypes in the two cell lines. 
However, PEA was shown to be elevated in HeLa cells after URB597 
treatment. This endocannabinoid analogue has been shown to transactivate 
P3$5Į DQG LWV DQWL-inflammatory actions have been demonstrated to be 
PHGLDWHG E\ 33$5Į DFWLYDWLRQ (LoVerme et al., 2005). Given that in HeLa 
cells, URB597 and OL135 elicited transactivatiRQRQO\RIWKH33$5Ȗ isotype, 
it would appear that other ECs or indeed other FAAH-2 products are involved 
in this mechanism. However, it remains unclear why higher concentrations of 
85% ZHUH LQHIIHFWLYH LQ WUDQVDFWLYDWLQJ 33$5Ȗ as shown by the bell-
shaped curve (Figure 5.3). On the contrary, URB597 appeared to inhibit the 
basal activation of both 33$5Į and 33$5ȕ, once again indicating how some 
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of the FAAH-2 substrates might represent a pool of endogenous ligands to 
these receptors. 
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6. ACTIVATION OF PPARs BY 
OLEAMIDE 
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6.1. Introduction 
In the previous sections of this thesis, FAAH-2 expression in HeLa cells was 
reported, together with ODA hydrolysis that was inhibited by URB597 pre-
treatment. Although levels of OEA and AEA were not significantly affected, 
PEA levels were augmented in HeLa cells following URB597 exposure. 
Treatment with this FAAH-1/2 inhibitor led to PPARȖ activation. In order to 
investigate the potential role of ODA, in this part of the study, the capability of 
ODA to activate PPAR nuclear receptors was assessed.  
 
6.2. Results 
6.2.1.  PPAR transactivation in CHO cells 
ODA at 10 and 50 µM evoked a significant activation of 33$5Į33$5ȕDQG
33$5Ȗ UHFHSWRUV LQ &+2 FHOOV RYHU-expressing these nuclear receptors. This 
activation was concentration-dependent for all three receptors. ODA appeared 
WRKDYHWKHPRVWPDUNHGHIIHFWVRQ33$5ȕDQG33$5ȖUHFHSWRUV7KHKLJKHU
concentUDWLRQRI2'$WHVWHG0HYRNHG33$5ȕDFWLYDWLRQWR-fold of 
FRQWURODQG33$5ȖDFWLYDWLRQWR-fold of control (Figure. 6.1).  
 
Endocannabinoid metabolism and PPARs signalling 
 
Activation of PPARs by oleamide - 107 
 
 
Figure 6.1 33$5Į 33$5ȕ DQG 33$5Ȗ UHSRUWHU JHQH DVVD\ LQ WUDQVLHQWO\
transfected CHO cells. ODA, at 10 and 50 µM, was tested alongside DMSO as 
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vehicle control and either  ȝ0 WY14643,  ȝ0 GW0742 or  ȝ0
rosiglitazone as positive controls, respectively (n=6, * P<0.05, ** P<0.01, *** 
P<0.001; One-ZD\$129$ZLWK%RQIHUURQL¶V3RVW+RFWHVW 
 
6.2.2.  PPAR ligand binding 
The ability of ODA to bind directly to PPARs was then tested in vitro. ODA 
ZDVLQGHHGDEOHWRGLVSODFHIOXRUHVFHQW OLJDQGVIURPWKH33$5Į33$5ȕDQG
33$5Ȗ OLJDQG ELQGLQJ GRPDLQV LQ D FRQFHQWUDWLRQ-dependent fashion. 
However, ODA was not able to completely displace OLJDQG IURP WKH33$5Į
binding domain at the highest concentration tested (100 µM), while the IC50 
value for the positive control WY14643 was 3.8 x 10-7 M (1.4 x 10-7 to 1.0 x 
10-6). 6LPLODUO\2'$FRXOG QRWFRPSOHWHO\ GLVSODFH OLJDQG IURP WKH33$5ȕ
ligand binding domain either, while the IC50 value for the positive control 
GW0742 was 8.4 x 10-10 M (4.0 x 10-10 to 1.8 x 10-9). The IC50 value for ODA 
ELQGLQJWR33$5ȖZDV[-5 M (3.1 x 10-5 to 4.7 x 10-5), while the IC50 
value for the positive control rosiglitazone was 2.2 x 10-7 M (2.0 x 10-7 to 2.5 x 
10-7; Figure. 6.2). 
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Figure 6.2 33$5Į 33$5ȕ DQG 33$5Ȗ OLJDQG ELQGLQJ DVVD\ RI LQFUHDVLQJ
concentrations of ODA and either WY14643, GW0742 or rosiglitazone as 
positive controls respectively (n=2, WY14643 n=1; one-site competition 
binding) 
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6.2.3.  Differentiation of 3T3-L1 cells 
In an Oil Red O uptake-based assay, ODA, at 10-20 µM, was able to induce 
differentiation of 3T3-L1 mouse fibroblast cells into adipocytes. The number 
of cells stained by the lipid-sensitive dye was indeed much higher in the ODA 
WUHDWHG ZHOOV FRPSDUHG WR WKH YHKLFOH WUHDWHG ZHOOV +RZHYHU WKH 33$5Ȗ
ligand rosiglitazone (10 µM) had a more marked effect on the treated cells 
(Figure.6.3).  
 
 
        Control       Rosiglitazone 10µM         ODA 10µM         ODA 20µM  
 
Figure 6.3: 3T3-L1 differentiation into adipocytes after treatment with ODA 
10-20 ȝM, rosiglitazone 10 ȝM as a positive control or DMSO as vehicle 
control (Picture shows one of three replicates). 
 
6.3. Discussion 
In this study, a further endocannabinoid-like molecule, oleamide, was shown 
to be able to occupy and activate PPAR nuclear receptors. As well as the 
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phytocannabinoids THC (O'Sullivan et al., 2005), the major psychoactive 
ingredient in cannabis, and cannabidiol (O'Sullivan et al., 2009), a number of 
endogenous cannabinoids have been shown to activate PPARs. In particular, 
anandamide, virodhamine, N-arachidonoyldopamine, noladin and 2-
arachidonoylglycerol, as well as N-oleoylethanolamine and N-
palmitoylethanolamine, have been shown to activate various members of the 
PPAR family (O'Sullivan, 2007). ǻ9-tetrahydrocannabinol (THC), the main 
active ingredient found in the Cannabis plant, has been shown to produce a 
time dependent vasorelaxation in vitro in isolated rat blood vessels through 
DFWLYDWLRQRI33$5Ȗ2
6XOOLYDQHWDO5). ODA has also been reported to 
induce vasorelaxation in the rat small mesenteric artery in vitro through 
activation of an undefined receptor which may be coupled to Ca2+-sensitive K+ 
channels and Gi/o (Hoi et al., 2006). However, the mechanism by which it 
elicits vasorelaxation has not been fully explained. ODA can inhibit gap 
junction formation (Boger et al., 1998), modulate GABA (Yost et al., 1998) 
and 5-HT (Thomas et al., 1998) receptors in vitro. Moreover, ODA has been 
demonstrated to bind to the CB1 receptor in vitro (Leggett et al., 2004). 
 
Results from the present study showed that ODA was able to transactivate 
33$5Į 33$5ȕ DQG 33$5Ȗ QXFOHDU UHFHSWRUV LQ D FRQFHQWUDWLRQ-dependent-
fashion with a lower potency than the respective selective ligands WY14643, 
GW0742 and rosiglitazone (Figure 6.1). ODA itself was able to occupy the 
ligand binding domain of all three receptors, implying that the enzymatic 
generation of oleic acid from ODA is not a simple explanation for the observed 
effects. Of the three subtypes of PPAR, the potency of ODA appeared highest 
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DW33$5Ȗ)LJXUH6.DOWKRXJKIXQFWLRQDOHIIHFWVRQ33$5ȕDSSHDUHGKLJKHU
in reporter gene assays (Figure 6.1). This may be attributed to greater 
DPSOLILFDWLRQ RI 33$5ȕ-evoked responses, or alternatively, to relatively 
eleYDWHGEDFNJURXQGOHYHOVRI33$5ȖDFWLYLW\ 
 
In order to explore the possibility of ODA being responsible for the reported 
PPARȖ activation by the FAAH inhibitor URB597 in HeLa cells (see Chapter 
5), attempts to measure ODA levels in these cells by LC-MS/MS have been 
made by Dr Leonie Norris in the School of Pharmacy (University of 
Nottingham). Unfortunately, measurements of ODA internal standards were 
not linear.  
 
The actual physiological significance of PPAR activation by ODA remains to 
be addressed. In order to at least partly address this issue, the ability of ODA to 
induce 3T3-L1 differentiation into adipocytes was demonstrated in this study 
(Figure 6. $GLSRJHQHVLV LV D ZHOO UHFRJQLVHG 33$5Ȗ PHGLDWHG DFWLYLW\
(Mueller et al., 2002). The proposed novel site of action for ODA through 
PPAR activation might be involved in some of the previously reported ODA 
effects. The onset of the vasorelaxation by ODA shown by (Hoi et al., 2006) 
was described to be too quick (on a time scale of ca. 5 min) to involve 
activation of nuclear receptors. The reported vasorelaxant effect of THC 
WKURXJK33$5Ȗ LQ LVROated rat blood vessels has also been shown to be time-
dependent (O'Sullivan et al., 2005). However, there is strong debate around the 
possibility of PPARs having non-genomic effects that would have a quicker 
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onset. Moreover, a late component of the vasorelaxation elicited by ODA 
might be due to nuclear receptor activation and this possibility has not been 
tested yet. Effects of N-oleoylethanolamine (OEA) and N-
palmitoylethanolamine, two other endocannabinoid-related molecules, in vivo 
KDYHEHHQGHPRQVWUDWHGWREHPHGLDWHGWKURXJK33$5ĮDFWLYDWion (Fu et al., 
2003) (LoVerme et al., 2006). OEA has also been reported to elicit loss of 
appetite and to reduce body weight gain in mice with a mechanism dependent 
RQ33$5Į(Fu et al., 2003) (Fu et al., 2003; Sun et al., 2006). Moreover, it has 
been previously shown that OEA pre-treatment reduced infarct volume from 
middle cerebral artery occlusion in wild-typH EXW QRW LQ 33$5Į-null, mice 
(Sun et al., 2007). In these two studies, OEA was shown to bind to the ligand 
ELQGLQJ GRPDLQ RI 33$5Į DQG WR WUDQVDFWLYDWH ERWK 33$5Į DQG 33$5ȕ
KRZHYHU LW KDG QR HIIHFW RQ 33$5Ȗ Data from the present study show that 
ODA binds to all three PPAR LBDs showinJKLJKHUDIILQLW\ IRU33$5ȖRYHU
the two other receptors (Figure 6.2). OEA and ODA share the same fatty acid 
chain, oleic acid, which, together with a variety of other saturated and 
XQVDWXUDWHG IDWW\ DFLGV LV RQH RI WKH 33$5Į QDWXUDO OLJDQGV %\ FRQWUDVW 
33$5Ȗ is less tolerant of structural variety WKDQ 33$5Į DQG LV XVXDOO\
activated by polyunsaturated fatty acids (Berger et al., 2002). Even if the 
limiting factor for PPAR binding is usually the length and saturation level of 
the fatty acid chain, in this case the head residue would appear to confer 
VHOHFWLYLW\ EHWZHHQ 2($ DQG 2'$ LQ 33$5Ȗ binding. However, no direct 
evidence is available in the literature of OEA binding (or not) to the ligand 
ELQGLQJGRPDLQRI33$5Ȗ 
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In summary, PPARs were identified as a novel site of action of ODA. Data in 
this study indicated that ODA could be regarded as a low affinity pan-PPAR 
ligand in vitro, being able to transactivate all three isotypes of this nuclear 
UHFHSWRUIDPLO\2'$DSSHDUHGWREHPRVWSRWHQWDVDOLJDQGRI33$5Ȗ 
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7. GENERAL DISCUSSION 
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Fatty Acid Amide Hydrolyse (FAAH) is the enzyme that hydrolyses ECLs of 
the NAE family. It plays a major role in controlling ECL physiological 
concentrations and signalling (McKinney et al., 2005). Neurones expressing 
FAAH in the rat brain are usually found in close proximity to axon terminals 
containing CB1 receptors, highlighting the role of FAAH in synaptic AEA 
inactivation (Suárez et al., 2008). Moreover, FAAH knockout mice have 
higher levels of AEA in the brain and show signs of an exaggerated 
endocannabinoid tone, such as reduced pain sensation (Cravatt et al., 2001). 
These findings suggest that inhibition of FAAH might augment AEA levels in 
discrete brain regions where this endogenous lipid is constitutively active, for 
example those engaged in the processing of pain. Indeed, FAAH inhibition is 
anti-nociceptive in models of acute and inflammatory pain (Fegley et al., 2005; 
Holt et al., 2005; Kathuria et al., 2003; Russo et al., 2007). FAAH is a 
promising drug target for pain treatment because it might allow the avoidance 
of undesirable central side effects associated with CB receptor activation. For 
example, its inhibition by URB597 increases AEA levels in the brain without 
inducing immobility, hypothermia or over-eating at doses that are effective at 
abrogating pain (Kathuria et al., 2003; Piomelli et al., 2006). Moreover, no 
rewarding effects are produced after FAAH inhibition by URB597 and this 
compound does not substitute for cannabinoid agonists in a rat drug 
discrimination test (Gobbi et al., 2005). Recently, in vivo effects of FAAH 
inhibition by URB597 such as analgesia, enhancement of memory acquisition 
and suppression of nicotine-induced excitation of dopamine cells have been 
linked to PPAR activation (Jhaveri et al., 2008; Mazzola et al., 2009; Melis et 
al., 2008). 
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Other authors previously reported how a variety of ECs and related molecules 
can bind to and activate PPARs when administered exogenously (O'Sullivan, 
2007). The aim of the present work was to test the possibility of elevating 
intracellular levels of ECLs by inhibiting their metabolism and check whether 
this augmentation in ECLs levels would lead to activation of PPARs nuclear 
receptors. In this study, it was indeed demonstrated that in intact SH-SY5Y 
human neuroblastoma cells (a model of neuronal cells), sustained FAAH 
inhibition by URB597 (~75 %) leads to accumulation of AEA, 2AG & PEA, 
but not OEA (see Chapter 4). Treatment with URB597, OL135 or PF750, three 
structurally and functionally distinct FAAH inhibitors, induces activation of 
endogenously expressed PPARs while no activation is observed in FAAH-1 
negative HeLa cells. Furthermore, exposure to URB597, OL135 or PF750 
leads to activation of over-expressed PPARs in SH-SY5Y cells. In the case of 
over-H[SUHVVHG 33$5ȕ WKLV DFWLYDWLRQ ZDV FOHDUO\ concentration-dependent 
and it was reversed by a selective antagonist. However, concentrations of 
85%UHTXLUHGWRHYRNH33$5ȕDFWLYDWLRQH[FHHGHGFRQFHQWUDWLRQVQHHGHG
to inhibit FAAH activity (see Chapter 5). Higher concentrations of URB597 
might be required to either inhibit the activity of newly synthesised FAAH or 
to inhibit the residual AEA hydrolysing activity that seems to be due to NAAA 
activity. To rule out direct activation of PPARs by URB597, cell-free binding 
DVVD\V VKRZHG WKDW 85% FRXOG QRW ELQG WR 33$5Į 33$5ȕ RU 33$5Ȗ
85% 2/ DQG 3) ZHUH DOO XQDEOH WR ELQG WR 33$5ȕ ELQGLQJ
domain, while AEA and 2-AG are ligands. In conclusion, activation of PPARs 
and, in particular of PPARȕ, with URB597 in intact cells appears to be 
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mediated through elevations of AEA and/or 2AG via FAAH-dependent and -
independent (NAAA) mechanisms. Surprisingly, treatment with URB597 in 
HeLa cells led to intracellular PEA accumulation but not AEA, OEA or 2AG. 
This might be due to inhibition of either FAAH-2 or NAAA that are both 
expressed in HeLa cells (see Chapter 3). Moreover, both URB597 and OL135 
could activate PPARȖ receptors over-expressed in HeLa cells. ODA, the main 
substrate for FAAH-2, was shown to bind to and activate all three PPARs in 
vitro (see Chapter 6). Thus, it is possible that either PEA or ODA were 
responsible for PPARȖ activation in HeLa cells after URB597 treatment. 
However, there is no evidence that PEA can bind to PPARȖ and this isotype is 
usually selectively activated by polyunsaturated fatty acids (Berger et al., 
2002). Moreover, it is reported that PEA could not transactivate PPARȖ in a 
reporter gene assay in HeLa cells (LoVerme et al., 2005). 
 
In the present study, transactivation of PPARs was monitored by measuring 
luciferase expression after 24 hours treatment in order to allow accumulation 
of intracellular ECs and transcription of the reporter gene (see Chapter 2). 
However, it is likely that in this time course ECL metabolism through 
oxidative metabolism via COX-2, 12-LOX or 15-LOX (Bisogno et al., 2005) 
could generate oxy-metabolites that might be PPAR ligands in their own right. 
Indeed, it has been demonstrated that a COX-2 metabolite of 2AG inhibits IL-
VHFUHWLRQ LQDFWLYDWHG7FHOOV WKURXJK33$5ȖDFWLYDWLRQ LQGHSHQGHQWRI WKH
cannabinoid receptors (Rockwell et al., 2006b). Moreover, a 15-LOX 
metabolite of 2AG (15-HETE-G) has been identified as D 33$5Į DJRQLVW
(Kozak et al., 2002). Furthermore, inhibition of IL-2 in murine splenocytes 
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ZDV VXJJHVWHG WR EH PHGLDWHG WKURXJK DFWLYDWLRQ RI 33$5Ȗ E\ D &2;-2 
metabolite of AEA (Rockwell et al., 2004). Another possible mechanism of 
PPAR activation after elevation of intracellular ECLs is the activation of CB 
receptors that are linked to downstream activation of the MAP kinase pathway 
(Demuth et al., 2006). All three of the well known MAPK family members 
(ERK, p38, and JNK) are known to phosphorylate PPARs leading to changes 
in transcriptional activity (Gardner et al., 2005) 
 
In the literature, it is widely accepted that AEA and 2AG, the two main ECs, 
are produced on demand and not stored in vesicles. This assumption is based, 
at least in the case of AEA, on the low basal concentration compared to other 
neurotransmitters and on the fact that AEA and N-arachidonyl PE biosynthesis 
is associated with stimulus-dependent release of AEA from neurones itself 
(Piomelli et al., 1998). Moreover, the activity of the semi-purified biosynthetic 
enzyme NAPE-PLD was shown to be activated by high concentrations of Ca2+ 
(Wang et al., 2006). The elevation of AEA, PEA and 2AG in SH-SY5Y cells 
and of PEA in HeLa cells reported here after inhibition of either FAAH or 
FAAH-2 and possibly NAAA (see Chapter 4), indicates for the first time to my 
knowledge, that it is possible to elevate ECs levels in cultured cells by simply 
modulating their metabolism. This would point in favour of an underlying ECL 
tone, at least in cultured cells, regardless of external stimulation. The failure of 
the RNAi approach to completely knock down FAAH mRNA levels does not 
allow an irrefutable link between the reported intracellular ECs elevation and 
subsequent PPARs activation to inhibition of this enzyme. However, in this 
study a thorough pharmacological approach was carried out by employing 
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three structurally and pharmacologically distinct FAAH inhibitors. 
Involvement of carboxylesterases, off-target actions of URB597 and OL135 
(Zhang et al., 2007), was ruled out using PF750. This compound belongs to a 
novel class of FAAH inhibitors whose greater selectivity has been identified in 
mouse and human proteomes (Ahn et al., 2007) 
 
The increase in AEA, PEA and 2AG levels after URB597 treatment in SH-
SY5Y cells reported in this study (see Chapter 4) is not as marked as reported 
in other ex vivo studies. (Fegley et al., 2005) reported that in rat brain AEA 
levels were trebled and both OEA and PEA levels were around four times 
higher following URB597 treatment. Here it is reported that in SH-SY5Y cells, 
AEA and 2AG levels were doubled after URB597 treatment, while PEA levels 
were only slightly increased. However, these results are in accordance with 
levels measured in mixed cultures of neurones and astrocytes after AMPA or 
NMDA treatment. AEA, 2AG and PEA were elevated in quantities comparable 
to the ones showed in the present study (Loría et al., 2009). Moreover, ECL 
levels were measured only after 24 hours treatment in the present study. It is 
likely that the intracellular concentration of ECs will vary after URB597 
treatment as a function of time. Moreover, the fact that different ECL appear to 
be elevated in SH-SY5Y cells after URB597 treatment compared to other ex 
vivo studies can be explained by a different site-specific availability of the 
various phospholipid precursors as well as possible distinct biosynthetic 
pathways.  
 
Endocannabinoid metabolism and PPARs signalling 
 
General Discussion - 121 
 
Both AEA and 2AG are reported here to be ligands of 33$5ȕ ZKLOH 2'$
appears to be a pan-PPAR ligand (see Chapter 5 and 6). However, their IC50 
are on the mid-micromolar range and the slight increase observed in ECL 
levels after URB597 treatment (see Chapter 4) might not appear enough to 
explain PPAR transactivation. Nevertheless, it was previously shown by a 
colleague in my lab how heterologous expression of fatty acid binding protein 
(FABP) 3 and 7 can selectively enhance activation of 33$5ĮDQG33$5Ȗ by 
exogenously administered OEA and AEA, respectively (Sun et al., 2008). 
Moreover, (Kaczocha et al., 2009) recently demonstrated that AEA uptake and 
hydrolysis were significantly potentiated in N18TG2 neuroblastoma cells after 
over-expression of FABP5 or FABP7. Taken together, these studies highlight 
the role of FABPs as AEA carriers. A similar chaperone system would explain 
how ECs that appear to only weakly bind to PPARs in cell-free systems and 
minimal differences in their intracellular concentration might lead to PPARs 
activation.  
 
The notion of a measurable EC tone in human cells and the possibility of a link 
between variation in intracellular ECs concentrations and PPAR activation 
might speculatively highlight a new role for these signalling lipids. PPARs are 
ZLGHO\UHFRJQLVHGDV³OLSLGVHQVRUV´SURYLGLQJDUHDG\WUDQVFULSWLRQDOUHVSRQVH
to changes in the available lipids pool (Berger et al., 2002). Intracellular ECLs 
would appear to be mainly regulated by FAAH (McKinney et al., 2005). So 
far, this enzyme has been shown to be regulated by FSH, leptin and 
progesterone (Maccarrone et al., 2003a; Maccarrone et al., 2003b; Rossi et al., 
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2007). ECs might represent the substrates that allow a cross-talk between these 
hormones and PPAR function.  
 
As previously mentioned, increasing evidence points towards a role for PPARs 
in mediating the anti inflammatory and analgesic effects of FAAH inhibition. 
The experiments presented in this study might be developed into models that 
would be useful to study the potential of new inhibitors of the EC metabolism 
in activating this pathway. Crucially, intracellular ECLs should be monitored 
after treatment with both OL135 and PF750 other than URB597 in order to 
strengthen the link between FAAH inhibition and PPARs transactivation. 
Moreover, timecourse experiments to monitor EC levels and PPARs activation 
should be carried out in order to better understand the relationship between 
these systems. The possibility of PPARs mediating the analgesic effect of 
FAAH inhibition is fascinating. However, this therapeutic approach is not 
without drawbacks. FAAH inhibition in vivo would indeed indiscriminately 
augment a variety of ECLs in the human body. Studying this mechanism in 
vivo could help us to develop novel FAAH inhibitors with selective effect on 
PPARs activation over CB receptors activation. As an example, URB597 
would also inhibit FAAH-2 in humans, possibly leading to accumulation of 
ODA other than the rest of ECLs. ODA accumulation might in turn lead to 
sleep induction, a major and unwanted side effect.  
 
The same model developed in this study might be used to test novel MGL 
inhibitors. However, inhibition of this enzyme might actually lead to even 
Endocannabinoid metabolism and PPARs signalling 
 
General Discussion - 123 
 
more marked central side effects. Indeedm, while FAAH inhibitors are largely 
inactive in the tetrad test, (Long et al., 2009) showed that a selective MGL 
inhibitor (JZL184) caused hypomotility when administered in mice. Dual 
inhibition of FAAH and MGL is not a feasible target either. Indeed, the same 
authors reported that this approach leads to a stronger analgesic effect than 
FAAH or MGL inhibition alone, but caused hypomotility, catalepsy and THC-
like effects in drug discrimination (Long et al., 2009). Conversely, as already 
mentioned no rewarding effects are produced after FAAH inhibition by 
URB597 and this compound does not substitute for cannabinoid agonists in a 
rat drug discrimination test (Gobbi et al., 2005). Long et al. (2009) concluded 
that the limited abuse potential of selective FAAH inhibitors compared to 
direct CB1 agonists may reflect a requirement for dual stimulation of AEA and 
2-AG pathways to produce the subjective effects of marijuana. 
 
Finally, it is worth mentioning that FAAH inhibition might not be a therapeutic 
strategy for analgesia only. Indeed, it is well recognised that ECLs up-
regulation exerts a protective action during inflammatory conditions. In a 
recent review of the therapeutic applications of the modulation of the EC 
system (Bifulco, 2009), it is outlined how pharmacological elevation of ECLs 
levels may be a promising strategy to counteract intestinal inflammation and 
colon cancer. Moreover, the involvement of the EC system and in particular of 
the FAAH enzyme in reproduction and fertility is presented as potential new 
target for infertility treatment (Bifulco, 2009). 
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Figure 7.1: Schematic representation of the pharmacological inhibition of 
FAAH that leads to augmentation of intracellular endocannabinoids (ECs) 
levels that in turn activate PPARs nuclear receptors.  
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8.1. ǯ 
Sequences in this chapter were copied and pasted from VectorNTI files. 
Human 33$5Į (CDS: 124-1530): 
       1 gttctggagg ctgggaagtt caagatcaaa gtgccagcag attcagtgtc atgtgaggac 
       61 gtgcttcctg cttcatagat aagagcttgg agctcggcgc acaaccagca ccatctggtc 
      121 gcgatggtgg acacggaaag cccactctgc cccctctccc cactcgaggc cggcgatcta 
      181 gagagcccgt tatctgaaga gttcctgcaa gaaatgggaa acatccaaga gatttcgcaa 
      241 tccatcggcg aggatagttc tggaagcttt ggctttacgg aataccagta tttaggaagc 
      301 tgtcctggct cagatggctc ggtcatcacg gacacgcttt caccagcttc gagcccctcc 
      361 tcggtgactt atcctgtggt ccccggcagc gtggacgagt ctcccagtgg agcattgaac 
      421 atcgaatgta gaatctgcgg ggacaaggcc tcaggctatc attacggagt ccacgcgtgt 
      481 gaaggctgca agggcttctt tcggcgaacg attcgactca agctggtgta tgacaagtgc 
      541 gaccgcagct gcaagatcca gaaaaagaac agaaacaaat gccagtattg tcgatttcac 
      601 aagtgccttt ctgtcgggat gtcacacaac gcgattcgtt ttggacgaat gccaagatct 
      661 gagaaagcaa aactgaaagc agaaattctt acctgtgaac atgacataga agattctgaa 
      721 actgcagatc tcaaatctct ggccaagaga atctacgagg cctacttgaa gaacttcaac 
      781 atgaacaagg tcaaagcccg ggtcatcctc tcaggaaagg ccagtaacaa tccacctttt 
      841 gtcatacatg atatggagac actgtgtatg gctgagaaga cgctggtggc caagctggtg 
      901 gccaatggca tccagaacaa ggaggcggag gtccgcatct ttcactgctg ccagtgcacg 
      961 tcagtggaga ccgtcacgga gctcacggaa ttcgccaagg ccatcccagg cttcgcaaac 
     1021 ttggacctga acgatcaagt gacattgcta aaatacggag tttatgaggc catattcgcc 
     1081 atgctgtctt ctgtgatgaa caaagacggg atgctggtag cgtatggaaa tgggtttata 
     1141 actcgtgaat tcctaaaaag cctaaggaaa ccgttctgtg atatcatgga acccaagttt 
     1201 gattttgcca tgaagttcaa tgcactggaa ctggatgaca gtgatatctc cctttttgtg 
     1261 gctgctatca tttgctgtgg agatcgtcct ggccttctaa acgtaggaca cattgaaaaa 
     1321 atgcaggagg gtattgtaca tgtgctcaga ctccacctgc agagcaacca cccggacgat 
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     1381 atctttctct tcccaaaact tcttcaaaaa atggcagacc tccggcagct ggtgacggag 
     1441 catgcgcagc tggtgcagat catcaagaag acggagtcgg atgctgcgct gcacccgcta 
     1501 ctgcaggaga tctacaggga catgtactga gttccttcag atcagccaca ccttttccag 
     1561 gagttctgaa gctgacagca ctacaaagga gacgggggag cagcacgatt ttgcacaaat 
     1621 atccaccact ttaaccttag agcttggaca gtctgagctg taggtaaccg gcatattatt 
     1681 ccatatcttt gttttaacca gtacttctaa gagcatagaa ctcaaatgct g 
 
Cloning Primers: 
Forward: ATAGGATCCTCGCGATGGTGGACACGGAA (BamHI) 
Reverse: ATAAGGGCCCCCTGGAAAAGGTGTGGCTGATCTG (ApaI) 
Lenght: 1443bp 
 
Human PPARȕ (CDS: 310-1635): 
        1 gcggagcgtg tgacgctgcg gccgccgcgg acctggggat taatgggaaa agttttggca 
       61 ggagcgggag aattctgcgg agcctgcggg acggcggcgg tggcgccgta ggcagccggg 
      121 acagtgttgt acagtgtttt gggcatgcac gtgatactca cacagtggct tctgctcacc 
      181 aacagatgaa gacagatgca ccaacgaggc tgatgggaac caccctgtag aggtccatct 
      241 gcgttcagac ccagacgatg ccagagctat gactgggcct gcaggtgtgg cgccgagggg 
      301 agatcagcca tggagcagcc acaggaggaa gcccctgagg tccgggaaga ggaggagaaa 
      361 gaggaagtgg cagaggcaga aggagcccca gagctcaatg ggggaccaca gcatgcactt 
      421 ccttccagca gctacacaga cctctcccgg agctcctcgc caccctcact gctggaccaa 
      481 ctgcagatgg gctgtgacgg ggcctcatgc ggcagcctca acatggagtg ccgggtgtgc 
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      541 ggggacaagg catcgggctt ccactacggt gttcatgcat gtgaggggtg caagggcttc 
      601 ttccgtcgta cgatccgcat gaagctggag tacgagaagt gtgagcgcag ctgcaagatt 
      661 cagaagaaga accgcaacaa gtgccagtac tgccgcttcc agaagtgcct ggcactgggc 
      721 atgtcacaca acgctatccg ttttggtcgg atgccggagg ctgagaagag gaagctggtg 
      781 gcagggctga ctgcaaacga ggggagccag tacaacccac aggtggccga cctgaaggcc 
      841 ttctccaagc acatctacaa tgcctacctg aaaaacttca acatgaccaa aaagaaggcc 
      901 cgcagcatcc tcaccggcaa agccagccac acggcgccct ttgtgatcca cgacatcgag 
      961 acattgtggc aggcagagaa ggggctggtg tggaagcagt tggtgaatgg cctgcctccc 
     1021 tacaaggaga tcagcgtgca cgtcttctac cgctgccagt gcaccacagt ggagaccgtg 
     1081 cgggagctca ctgagttcgc caagagcatc cccagcttca gcagcctctt cctcaacgac 
     1141 caggttaccc ttctcaagta tggcgtgcac gaggccatct tcgccatgct ggcctctatc 
     1201 gtcaacaagg acgggctgct ggtagccaac ggcagtggct ttgtcacccg tgagttcctg 
     1261 cgcagcctcc gcaaaccctt cagtgatatc attgagccta agtttgaatt tgctgtcaag 
     1321 ttcaacgccc tggaacttga tgacagtgac ctggccctat tcattgcggc catcattctg 
     1381 tgtggagacc ggccaggcct catgaacgtt ccacgggtgg aggctatcca ggacaccatc 
     1441 ctgcgtgccc tcgaattcca cctgcaggcc aaccaccctg atgcccagta cctcttcccc 
     1501 aagctgctgc agaagatggc tgacctgcgg caactggtca ccgagcacgc ccagatgatg 
     1561 cagcggatca agaagaccga aaccgagacc tcgctgcacc ctctgctcca ggagatctac 
     1621 aaggacatgt actaacggcg gcacccaggc ctccctgcag actccaatgg ggccagcact 
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     1681 ggaggggccc acccacatga cttttccatt gaccagccct tgagcacccg gcctggagca 
     1741 gcagagtccc acgatcgccc tcagacacat gacacccacg gcctctggct ccctgtgccc 
     1801 tctctcccgc ttcctccagc cagctctctt cctgtctttg ttgtctccct ctttctcagt 
     1861 tcctctttct tttctaattc ctgttgctct gtttcttcct ttctgtaggt ttctctcttc 
     1921 ccttctccct tgccctccct ttctctctcc accccccacg tctgtcctcc tttcttattc 
     1981 tgtgagatgt tttgtattat ttcaccagca gcatagaaca ggacctctgc ttttgcacac 
     2041 cttttcccca ggagcagaag agagtggggc ctgccctctg ccccatcatt gcacctgcag 
     2101 gcttaggtcc tcacttctgt ctcctgtctt cagagcaaaa gacttgagcc atccaaagaa 
     2161 acactaagct ctctgggcct gggttccagg gaaggctaag catggcctgg actgactgca 
     2221 gccccctata gtcatggggt ccctgctgca aaggacagtg ggcaggaggc cccaggctga 
     2281 gagccagatg cctccccaag actgtcattg cccctccgat gctgaggcca cccactgacc 
     2341 caactgatcc tgctccagca gcacacctca gccccactga cacccagtgt ccttccatct 
     2401 tcacactggt ttgccaggcc aatgttgctg atggccccct gcactggccg ctggacggca 
     2461 ctctcccagc ttggaagtag gcagggttcc ctccaggtgg gcccccacct cactgaagag 
     2521 gagcaagtct caagagaagg aggggggatt ggtggttgga ggaagcagca cacccaattc 
     2581 tgcccctagg actcggggtc tgagtcctgg ggtcaggcca gggagagctc ggggcaggcc 
     2641 ttccgccagc actcccactg cccccctgcc cagtagcagc cgcccacatt gtgtcagcat 
     2701 ccagggccag ggcctggcct cacatccccc tgctcctttc tctagctggc tccacgggag 
     2761 ttcaggcccc actccccctg aagctgcccc tccagcacac acacataagc actgaaatca 
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     2821 ctttacctgc aggctccatg cacctccctt ccctccctga ggcaggtgag aacccagaga 
    2881 gaggggcctg caggtgagca ggcagggctg ggccaggtct ccggggaggc aggggtcctg 
    2941 caggtcctgg tgggtcagcc cagcacctgc tcccagtggg agcttcccgg gataaactga 
    3001 gcctgttcat tctgatgtcc atttgtccca atagctctac tgccctcccc ttccccttta 
    3061 ctcagcccag ctggccacct agaagtctcc ctgcacagcc tctagtgtcc ggggaccttg 
    3121 tgggaccagt cccacaccgc tggtccctgc cctcccctgc tcccaggttg aggtgcgctc 
    3181 acctcagagc agggccaaag cacagctggg catgccatgt ctgagcggcg cagagccctc 
    3241 caggcctgca ggggcaaggg gctggctgga gtctcagagc acagaggtag gagaactggg 
    3301 gttcaagccc aggcttcctg ggtcctgcct ggtcctccct cccaaggagc cattctgtgt 
    3361 gtgactctgg gtggaagtgc ccagcccctg cccctacggg cgctgcagcc tcccttccat 
    3421 gccccaggat cactctctgc tggcaggatt cttcccgctc cccacctacc cagctgatgg 
    3481 gggttggggt gcttcctttc aggccaaggc tatgaaggga cagctgctgg gacccacctc 
    3541 cccctccccg gccacatgcc gcgtccctgc cccgacccgg gtctggtgct gaggatacag 
    3601 ctcttctcag tgtctgaaca atctccaaaa ttgaaatgta tatttttgct aggagcccca 
    3661 gcttcctgtg tttttaatat aaatagtgta cacagactga cgaaacttta aataaatggg 
    3721 aattaaatat ttaa 
 
Cloning Primers: 
Forward: ATAGGATCCAGATCAGCCATGGAGCAGCC (BamHI) 
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Reverse: ATATCTAGAGCCTGGGTGCCGCCGTTAGT (XbaI) 
Lenght: 1331bp 
 
Human PPARȖ2 (CDS: 91-1608): 
1 tccggttttt ttcttttaac ggattgatct tttgctagat agagacaaaa tatcagtgtg  
61 aattacagca aacccctatt ccatgctgtt atgggtgaaa ctctgggaga ttctcctatt  
121 gacccagaaa gcgattcctt cactgataca ctgtctgcaa acatatcaca agaaatgacc  
181 atggttgaca cagagatgcc attctggccc accaactttg ggatcagctc cgtggatctc  
241 tccgtaatgg aagaccactc ccactccttt gatatcaagc ccttcactac tgttgacttc  
301 tccagcattt ctactccaca ttacgaagac attccattca caagaacaga tccagtggtt  
361 gcagattaca agtatgacct gaaacttcaa gagtaccaaa gtgcaatcaa agtggagcct  
421 gcatctccac cttattattc tgagaagact cagctctaca ataagcctca tgaagagcct  
481 tccaactccc tcatggcaat tgaatgtcgt gtctgtggag ataaagcttc tggatttcac  
541 tatggagttc atgcttgtga aggatgcaag ggtttcttcc ggagaacaat cagattgaag  
601 cttatctatg acagatgtga tcttaactgt cggatccaca aaaaaagtag aaataaatgt  
661 cagtactgtc ggtttcagaa atgccttgca gtggggatgt ctcataatgc catcaggttt  
721 gggcggatgc cacaggccga gaaggagaag ctgttggcgg agatctccag tgatatcgac  
781 cagctgaatc cagagtccgc tgacctccgg gccctggcaa aacatttgta tgactcatac  
841 ataaagtcct tcccgctgac caaagcaaag gcgagggcga tcttgacagg aaagacaaca  
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901 gacaaatcac cattcgttat ctatgacatg aattccttaa tgatgggaga agataaaatc  
961 aagttcaaac acatcacccc cctgcaggag cagagcaaag aggtggccat ccgcatcttt  
1021 cagggctgcc agtttcgctc cgtggaggct gtgcaggaga tcacagagta tgccaaaagc  
1081 attcctggtt ttgtaaatct tgacttgaac gaccaagtaa ctctcctcaa atatggagtc  
1141 cacgagatca tttacacaat gctggcctcc ttgatgaata aagatggggt tctcatatcc  
1201 gagggccaag gcttcatgac aagggagttt ctaaagagcc tgcgaaagcc ttttggtgac  
1261 tttatggagc ccaagtttga gtttgctgtg aagttcaatg cactggaatt agatgacagc  
1321 gacttggcaa tatttattgc tgtcattatt ctcagtggag accgcccagg tttgctgaat  
1381 gtgaagccca ttgaagacat tcaagacaac ctgctacaag ccctggagct ccagctgaag  
1441 ctgaaccacc ctgagtcctc acagctgttt gccaagctgc tccagaaaat gacagacctc  
1501 agacagattg tcacggaaca cgtgcagcta ctgcaggtga tcaagaagac ggagacagac  
1561 atgagtcttc acccgctcct gcaggagatc tacaaggact tgtactag 
 
Cloning Primers: 
Forward: ATTGGTACCCCATGCTGTTATGGGTGAAA (KpnI) 
Reverse: ACGTCTAGACTAGTACAAGTCCTTGTAGA (XbaI) 
Lenght: 1528bp 
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8.2. Primers and Probes 
Sequences in this chapter were copied and pasted from Primer Express files 
Human -actin:  
FW Primer: CCTGGCACCCAGCACAAT 
Tm: 59 % G/C: 61 Length: 18 
RV Primer: GCCGATCCACACGGAGTACT 
Tm: 59 % G/C: 60 Length: 20 
TaqMan Probe: ATCAAGATCATTGCTCCTCCTGAGCGC 
Tm: 69 % G/C: 52 Length: 27 
Amplicon: 
Tm: 82 %G/C: 56 Length: 70 
 
 
Human B2M:  
FW Primer: TGACTTTGTCACAGCCCAAGATA 
Tm: 58.9 % G/C: 43.5 Length: 23 
RV Primer: AATCCAAATGCGGCATCTTC 
Tm: 55.3 % G/C: 45 Length: 20 
TaqMan Probe: TGATGCTGCTTACATGTCTCGATCCCA 
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Tm: 65.0 % G/C: 48.1 Length: 27 
Amplicon: 
Length: 85 
 
 
Human GAPDH:  
FW Primer: CAACAGCCTCAAGATCATCAGC 
Tm: 60.3 % G/C: 50 Length: 22 
RV Primer: TGGCATGGACTGTGGTCATGAG 
Tm: 62.1 % G/C: 54.5 Length: 22 
TaqMan Probe: CCTGGCCAAGGTCATCCATGACAAC 
Tm: 66.3 % G/C: 56 Length: 25 
Amplicon: 
Length: 119 
 
 
Human CB1: 
FW Primer: GCCCATGTGGCTAAAAAAGC 
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Tm: 58 % G/C: 50 Length: 20 
RV Primer: CAATGCCAAGTGTATCGGTTCTT 
Tm: 59 % G/C: 43 Length: 23 
TaqMan Probe: AGACAGTGGATGAGACACACAACGGCA 
Tm: 69 % G/C: 52 Length: 27 
Amplicon: 
Tm: 79 %G/C: 48 Length: 79 
 
 
Human CB2:  
FW Primer: GCAGCGTGACTATGACCTTCAC   
Tm: 58  % G/C: 55 Length: 22 
RV Primer: GAGCTTTGTAGGAAGGTGGATAGC   
Tm: 59 % G/C: 50 Length: 24 
TaqMan Probe: TGACCGCCATTGACCGATACCTCTG 
Tm: 69 % G/C: 56 Length: 25 
Amplicon: 
Tm: 83 %G/C: 58 Length: 99 
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Human FAAH: 
FW Primer: TCGTTCGGCTGGAAAACTCT 
Tm: 59 % G/C: 50 Length: 20 
RV Primer: CTGGGCAATCACGGTTTTG 
Tm: 59 % G/C: 53 Length: 19 
TaqMan Probe: AACTGCAGCACGAGATCGAGGTGTACC 
Tm: 68 % G/C: 56 Length: 27  
Amplicon: 
Tm: 82 %G/C: 56 Length: 70 
 
 
Human FAAH2: 
FW Primer: GCCGAGCAGCTTTAGTCTTAGG 
Tm: 58 %G/C: 54.5 Length: 22 
RV Primer: CAACATCTATACATTTCACCTTTCTCTGT 
Tm: 58 %G/C: 34.5 Length 29 
TaqMan Probe: CAAAGTTTGCCTCAAAGACCCCTCGG 
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Tm: 69 %G/C: 53.8 Length: 26 
Amplicon: 
Tm: 81 Length: 138 
 
 
Human NAAA: 
FW Primer: CAGGAACTACTTTTATTGGCTATGTAGGA 
Tm: 59 %G/C: 37.9 Length: 29 
RV Primer: CCAGCCTTTATCTCGTTCATCAC 
Tm: 59 %G/C: 47.8 Length: 23 
TaqMan Probe: ACTGGCCAGAGCCCACACAAGTTTACAGTT 
Tm: 70 %G/C: 50 Length: 30 
Amplicon: 
Tm: 78 Length: 92 
 
 
Human MGL: 
FW Primer: CAGGACAAGACTCTCAAGATTTATGAA 
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Tm: 58% %G/C: 37 Length: 27 
RV Primer: TGTCCTTTGAGAGACCCACATG 
Tm: 59% %G/C: 50 Length 22 
TaqMan Probe: CTTCCTGAAGTCACCAACTCCGTCTTCCAT 
Tm: 69 %G/C: 50 Length: 30 
Amplicon: 
Tm: 78 Length: 114 
 
 
Human DAGLa: 
FW Primer: CCGGTGACCAGAAACACCAA 
Tm: 60% %G/C: 55 Length: 20 
RV Primer: GAGCATGTAGTAGCAGACCTCTTTG 
Tm: 58% %G/C: 48 Length 25 
TaqMan Probe: TCGACCTCAAGAATTCACAAGAGATGCTCC 
Tm: 69 %G/C: 46.7 Length: 30 
Amplicon: 
Tm: 80 Length: 84 
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Human 33$5Į:  
FW Primer: GCTTCCTGCTTCATAGATAAGAGCTT 
Tm: 61.6 % G/C: 42.3 Length: 26 
RV Primer: CACCATCGCGACCAGATG 
Tm: 58.2 % G/C: 61.1 Length: 18 
TaqMan Probe: AGCTCGGCGGCACAACCAGCA 
Tm: 65.7 % G/C: 66.7 Length: 21 
 
 
Human PPARȕ:  
FW Primer: TGCGGCCATCATTCTGTGT 
Tm: 56.7 % G/C: 52.6 Length: 19 
RV Primer: CAGGATGGTGTCCTGGATAGC 
Tm: 61.8 % G/C: 57.1 Length: 21 
TaqMan Probe: ACCGGCCAGGCCTCATGAACG 
Tm: 65.7 % G/C: 66.7 Length: 21 
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Human PPARȖ:  
FW Primer: GATTCTCCTATTGACCCAGAAAGC 
Tm: 64.8 % G/C: 46 Length: 24 
RV Primer: GCATCTCTGTGTCAACCATGGT 
Tm: 66.2 % G/C: 50 Length: 22 
TaqMan Probe: ATTCCTTCACTGATACACTGTCTGCAAACATAT 
Tm: 69.9 % G/C: 36 Length: 33 
 
 
8.3. RNAi constructs 
Anti-FAAH siRNA (Ambion): 
ID: s4961 
Sequence:  
Sense: GGCCUGGGAAGUGAACAAAtt 
Antisense: UUUGUUCACUUCCCAGGCCtt 
 
ID: s4963 
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Sequence: 
Sense: CUAUGAGACUGACAACUAUtt 
Antisense: AUAGUUGUCAGUCAGUCUCAUAGta 
 
 
Anti-FAAH siRNA (Dharmacon): 
 
ID: A-009907-14 
Sequence: GUCUCAAUUCUGAAGCUUC 
 
ID: A-009907-15 
Sequence: GCUUGAGCCUGAAUGAAGG 
 
ID: A-009907-16 
Sequence: CUUCAAAGGUGAUUUCGUG 
 
ID: A-009907-17 
Sequence: GGCUUAGGCACUGAUAUCG 
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Anti-FAAH shRNA (Sigma):  
ID: TRCN0000050633 
Sequence: 
CCGGCCACAGTCCATGTTCAGCTATCTCGAGATAGCTGAACATG
GACTGTGGTTTTTG 
 
ID:TRCN0000050634 
Sequence: 
CCGGGCTCTTCACCTATGTGGGAAACTCGAGTTTCCCACATAGG
TGAAGAGCTTTTTG 
 
ID:TRCN0000050635 
Sequence: 
CCGGCGTCAGCTACACTATGCTGTACTCGAGTACAGCATAGTGT
AGCTGACGTTTTTG 
 
ID:TRCN0000050637 
Sequence: 
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CCGGAGAAGAGTTGTGTCTGCGGTTCTCGAGAACCGCAGACAC
AACTCTTCTTTTTTG 
